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ACS acute coronary syndrome  
ATIII antithrombin III  
βhCG free β-form of human chorionic gonadotropin  
BNP brain-type natriuretic peptide 
BMP bone morphogenetic protein  
β-PDD β-phorbol 12,13-didecanoate 
BSA bovine serum albumin 
CAD coronary artery disease  
CCP complement control protein  
CI confidence interval  
CK-MB MB isoform of creatine kinase  
CRP C-reactive protein  
cTnI cardiac troponin I  
cTnT cardiac troponin T 
dB-cAMP dibutyryl cyclic adenosine monophosphate 
DNA deoxyribonucleic acid 
DS Down’s syndrome 
EC endothelial cells 
ECG electrocardiogram 
EDTA ethylenediaminetetraacetic acid  
FSH follicle stimulating hormone 
GAG glycosaminoglycan 
IGF insulin-like growth factor  
IGFBP insulin-like growth factor binding protein 
IGF-R1 type I IGF receptor  
IL interleukin  
KO knocked-out, the gene for the specified protein inactivated   
LDL low-density lipoprotein 
LMWH low molecular weight heparin 
LNR Lin-Notch repeat 
MBP major basic protein of eosinophils 
MI myocardial infarction 
MoM multiples of the median 
MPO myeloperoxidase 
mRNA messenger ribonucleic acid 
NODAT new-onset diabetes mellitus after transplantation 
NSTE-ACS ACS without ST-segment elevation in ECG  
NSTEMI MI without elevation of the ST-segment in ECG 
PAPP-A pregnancy-associated plasma protein A 
PAPP-A/proMBP  a heterotetrameric protein complex consisting of two PAPP-A subunits and two 
proMBP subunits  
PCI percutaneous coronary intervention 
PMA phorbol 12-myristate-13-acetate  
proMBP the proform of eosinophil major basic protein 
RT-PCR reverse transcription polymerase chain reaction 
SA stable angina 
SCR short consensus repeat 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
STEMI  myocardial infarction with elevation of the ST-segment in ECG  
TNFα tumor necrosis factor-α 
UA unstable angina  
UFH unfractionated heparin  




In recent years, one important objective of cardiovascular research has been to find new 
markers that would improve the risk stratification and diagnosis of patients presenting with 
symptoms of acute coronary syndrome (ACS). Pregnancy-associated plasma protein A 
(PAPP-A) is a large metalloproteinase involved in insulin-like growth factor signalling. It 
is expressed in various tissues and seems to be involved in many physiological and patho-
logical processes, such as folliculogenesis, bone formation, wound healing, pregnancy and 
atherosclerosis. The aim of this thesis was to investigate PAPP-A in ACS patients. 
Circulating concentrations of PAPP-A had been previously shown to be elevated in ACS. 
In this study it was revealed that the form of PAPP-A causing this elevation was the free 
noncomplexed PAPP-A. Thus, the form of PAPP-A in the circulation of ACS patients dif-
fered from the complexed PAPP-A form abundantly present in the circulation during preg-
nancy. A point-of-care method based on time-resolved immunofluorometric assays was 
developed, which enabled the rapid detection of free PAPP-A. The method was found to 
perform well with serum and heparin plasma samples as well as with heparinized whole 
blood samples. With this method the concentrations of free PAPP-A in healthy individuals 
were shown to be negligible. When the clinical performance of the method was evaluated 
with serum samples from ACS patients, it was shown that the free PAPP-A concentration 
in the admission sample was an independent predictor of myocardial infarction and death. 
Moreover, as a prognostic marker, free PAPP-A was revealed to be superior to total PAPP-
A, i.e. the combination of free and complexed PAPP-A, which has been measured by the 
other groups in this field. 
As heparin products are widely used as medication in ACS patients, the effect of heparin 
products on free PAPP-A molecule and circulating concentrations were also investigated in 
this study. It was shown that intravenous administration of low molecular weight or unfrac-
tionated heparin elicits a rapid release of free PAPP-A into the circulation in haemodialysis 
patients and patients undergoing angiography. Moreover, the interaction between PAPP-A 
and heparin was confirmed in gel filtration studies. Importantly, the patients included in the 
clinical evaluation of the free PAPP-A detection method developed had not received any 
heparin product medication before the admission sample and thus the results were not af-
fected by the heparin effect. 
In conclusion, free PAPP-A was identified as a novel marker associated with ACS. The 
point-of-care methods developed enable rapid detection of this molecule which predicts 
adverse outcome when measured in the admission sample of ACS patients. However, the 
effect revealed of heparin products on circulating PAPP-A concentrations should be ac-




Acute coronary syndromes (ACS) are a major cause of morbidity and mortality in the 
world today. Early diagnosis has a key role in limiting myocardial damage in ACS patients. 
Prompt risk stratification and diagnosis enable rapid initiation of therapy with the aggres-
siveness of the therapy in concordance with the risk of the patient for adverse outcome. 
Circulating markers of myocardial necrosis, most commonly cardiac troponins I and T 
(cTnI, cTnT) due to their superior sensitivity and tissue-specificity, are widely used in the 
diagnosis of ACS patients along with the electrocardiogram (ECG). (For reviews, see 
Maisel et al., 2006; Morrow et al., 2007; Bonaca and Morrow, 2008.) 
The limitation of cardiac troponins has been that as makers of myocardial necrosis they are, 
by definition, released into the circulation only after damage of the heart muscle tissue. 
Moreover, with the methods previously available, it took several hours after the onset of 
symptoms for the elevations to become detectable (Donnelly and Millar-Craig, 1998). 
However, the tests for cardiac troponins have lately evolved significantly and become more 
and more sensitive. This has enabled the detection of even lower elevations earlier in the 
course of ACS (Reichlin et al., 2009). On the other hand, this has also created problems in 
patient management (Fye, 2006; Jaffe et al., 2006; Bonaca and Morrow, 2008). With the 
sensitive assays cardiac troponin elevations are being detected in significantly larger pa-
tient populations with some of the patients not necessarily in need of aggressive therapy. 
Moreover, mild troponin elevations, although still indicating myocardial damage, can also 
be associated with other conditions without high imminent risk for irreversible adverse 
cardiac outcome (Panteghini, 2004).  
In recent years a major objective in cardiovascular disease research has been to find new 
biomarkers that would appear in the circulation before significant myocardial necrosis 
develops. Such markers are anticipated to enable earlier diagnosis or better risk stratifica-
tion of the patients arriving at the emergency unit with symptoms of ACS such as chest 
discomfort and shortness of breath. It is hoped that the new markers will provide better risk 
prediction especially in patients without cardiac troponin elevations on admission. More-
over, the new markers should aid in the management of patients who have only mild eleva-
tions in cardiac troponin measured by a sensitive assay but who do not necessarily need 
aggressive treatment with higher risk. Numerous candidate molecules have appeared which 
are linked to the various pathological processes leading to or associated with ACS. These 
include markers presumably related to inflammation, plaque destabilization, plaque rup-
ture, thrombosis, ischemia and myocardial dysfunction (for reviews, see Apple et al., 2005; 
Jaffe et al., 2006; Maisel et al., 2006; See and de Lemos, 2006; Bonaca and Morrow, 2008; 
O'Donoghue and Morrow, 2008). Lately, pregnancy-associated plasma protein A (PAPP-
A) has emerged as an interesting candidate marker in this context. 
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2 REVIEW OF THE LITERATURE 
The aim of this literature review is to give a comprehensive overview of what is currently 
known about the PAPP-A molecule, the association of PAPP-A with physiological and 
pathological processes and the use of PAPP-A as a circulating biomarker in different con-
ditions. 
2.1 Structure of PAPP-A 
2.1.1 Molecular structure 
PAPP-A was initially found in the plasma of pregnant women among three other highly 
abundant proteins by Lin and colleagues in 1974. The molecules were detected with anti-
third trimester pregnancy serum polyclonal antibodies not reactive with normal human 
serum and were alphabetically named (PAPP-A, PAPP-B, PAPP-C and PAPP-D) accord-
ing to their precipitation order in the immunodiffusion method used (Lin et al., 1974). 
Later it was revealed that the molecule detectable in pregnancy plasma that had been 
named PAPP-A was actually a covalent complex of PAPP-A and the proform of eosinophil 
major basic protein (proMBP) in equimolar amounts (Oxvig et al., 1993). More specifi-
cally, the molecule is a heterodimer consisting of two PAPP-A subunits and two proMBP 
subunits connected by disulfide bridges (PAPP-A/proMBP complex) (Oxvig et al., 1994b). 
However, PAPP-A produced in cell culture conditions is a homodimer of two PAPP-A 
subunits (Lawrence et al., 1999; Overgaard et al., 2000). 
In non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
PAPP-A/proMBP complex from pregnancy plasma migrates as a 500 kDa entity. Upon 
reduction PAPP-A subunit is seen at 200 kDa. However, proMBP forms a smear at 50-90 
kDa most likely because of high and variable glycosylation of this subunit. (Oxvig et al., 
1994a.) The calculated size of PAPP-A subunit is 199 kDa, when the determined protein 
and carbohydrate contents are taken into account. The calculated size of the PAPP-
A/proMBP complex is 474 kDa. (Oxvig et al., 1994b.) 
The gene of PAPP-A is found in human chromosome region 9q33.1 (Sinosich, 1990). 
PAPP-A is encoded by 22 exons (Overgaard et al., 2003) and the sequence of PAPP-A 
seems to be highly conserved between mammals (Mazerbourg et al., 2001; Hourvitz et al., 
2002). For example, between mouse and human the sequence identity is 91.1% (Soe et al., 
2002). Homology has also been noticed between human and zebrafish PAPP-A (Overgaard 
et al., 2003). 
PAPP-A is transcribed as an mRNA of 8400 nucleotides of which 4881 nucleotides are 
translated into preproPAPP-A of 1627 amino acids (Haaning et al., 1996). Thus the PAPP-
A transcript has an unusually long 5’ untranslated region. The preproform includes a puta-
tive signal peptide of 22 residues and a highly basic (calculated pI 12.9) propeptide of 58 
residues (Haaning et al., 1996). The PAPP-A propeptide is not required for folding or se-
cretion of the protein and the proform is most likely cleaved by a protease recognizing Arg-
X-X-Arg motif, possibly furin, prior to secretion (Kristensen et al., 1994; Overgaard et al., 
2000). The mature PAPP-A monomer polypeptide contains 1547 amino acid residues rep-
resenting the C-terminal part of the proform of PAPP-A (Kristensen et al., 1994). The 
structure of the mature PAPP-A polypeptide is shown in Figure 1. 
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Figure 1. The structure of PAPP-A polypeptide with the functional modules and important amino acids. 
(CCP1-5, the complement control protein modules 1-5 involved in surface binding; LNR1-3, Lin-Notch 
repeats important in substrate recognition and activity; LG, laminin G-like module of unknown function) 
In the amino acid sequence of the PAPP-A monomer there are 13 putative sites for N-
glycosylation and 7 putative sites for attachment of glycosaminoglycan groups (Kristensen 
et al., 1994). Of the 13 potential sites for N-linked carbohydrate 11 are substituted. How-
ever, PAPP-A is most likely not O-glycosylated (Overgaard et al., 2003). In pregnancy 
serum there are 44 N-acetylglucosamine monosaccharides for each PAPP-A polypeptide 
chain (Overgaard et al., 2000). In recombinantly produced PAPP-A, however, the degree 
of glycosylation has been reported to be lower (Overgaard et al., 2000). 
There are 82 Cys residues in the amino acid sequence of the mature PAPP-A monomer 
(Kristensen et al., 1994). Cys-1130 is responsible for the covalent dimerization of PAPP-A 
monomers while Cys-381 and Cys-652 are involved in the complexation with proMBP and 
are free in PAPP-A dimer (Overgaard et al., 2003; Glerup et al., 2005). All other cysteines 
seem to form intrachain bridges within structural domains except Cys-563, for which the 
status is unknown (Overgaard et al., 2003). 
Recently, some proteins with sequence homology with PAPP-A have been identified. A 
previously unknown protein found in 2001 in a search of public DNA sequence databases 
showed 46% homology with PAPP-A and was thus named PAPP-A2 (Overgaard et al., 
2001). A splicing variant of PAPP-A with a highly basic 29-residue insert at an exon junc-
tion was detected in mice in 2002 and was accordingly named PAPP-Ai (Soe et al., 2002). 
Furthermore, an archaeal protein resembling PAPP-A, ulilysin of Methanosarcina 
acetivorans, was recently found in a bioinformatic search in which structure prediction was 
utilized (Tallant et al., 2006). With a molecular size of 29-kDa this protein seems to consist 
only of a catalytic domain similar to that of PAPP-A. Although the sequence homology is 
not high, the key residues important for catalysis, substrate binding and structural stability 
are fully conserved between PAPP-A and ulilysin (Tallant et al., 2006). 
Apart from these proteins, no homology has been detected with other proteins apart from 
certain structural module similarities which will be discussed in the following section. It is 
noteworthy that the sequence of PAPP-A is not related to α-2-macroglobulin, although in 
some early reports published in the 1980s these proteins were assumed to be alike. This 
faulty assumption arose from certain similar physical properties including molecular 
weight, amino acid composition, isoelectric point and electrophoretic mobility (Sutcliffe et 
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2.1.2 Functional modules 
Proteolytic domain 
A putative Zn2+ binding site similar to that found in the metalloproteinases belonging to the 
metcinzin superfamily (astacins, reprolysins/adamalysins, serralysins, matrix metallopro-
teinases) has been identified in the amino acid sequence of PAPP-A (Kristensen et al., 
1994). PAPP-A has the elongated zinc-binding motif conserved between metzincins, 
HEXXHXXGXXH (from His-482 to His-492, HEIGHSLGLYH in the sequence of PAPP-
A), which coordinates the catalytic zinc ion with three His residues (Boldt et al., 2001). 
The importance of this sequence for the activity of PAPP-A has been confirmed in muta-
tion studies as the substitution of Glu-483 with Ala (E483A) renders PAPP-A inactive 
(Boldt et al., 2001). 
In addition to the elongated zinc-binding motif, PAPP-A also contains another metzincin 
defining structure: a Met-turn presumed to interact directly with the residues of the active 
zinc-binding site (Boldt et al., 2001). The Met-turn of PAPP-A is located 63 residues apart 
from the zinc-binding motif (Met-556) the distance being, however, unusually long for 
metzincins (Boldt et al., 2001). In addition, contrary to other metzincins, the family-
specific residue following the third His residue of the zinc-binding motif is Val, and Asn is 
found two residues before the Met of the Met-turn (Boldt et al., 2001). With secondary 
structure prediction, PAPP-A was found to have a topology similar to metzincins with three 
α-helices and five β-strands common to metzincins within a 312-residue sequence stretch 
from Val-272 to Tyr-583 that defines the proteolytic domain of PAPP-A (Boldt et al., 
2001). However, PAPP-A contains more intradomain disulfide bonds within the proteolytic 
domain than the other known members of metzincins (Overgaard et al., 2003). Due to these 
differences, PAPP-A was suggested to be the founder member of a new family within the 
metzincin superfamily, pappalysins, and was named pappalysin-1 (Boldt et al., 2001). The 
three-dimensional structure of ulilysin has been revealed which gives a suggestive model of 
the structure of the catalytic site of PAPP-A (Tallant et al., 2006).  
Complement control protein modules 
In the C-terminal part of PAPP-A there are five motifs of ~60 residues that are related to 
the short consensus repeat (SCR) modules found in complement proteins and selectins 
(Kristensen et al., 1994). In complement proteins these motifs, which are also known as 
complement control protein (CCP) modules, contain four cysteines. However, the CCP 
modules of PAPP-A contain 6 Cys residues as do the CCP modules of selectins (Overgaard 
et al., 2003).  
Laursen and colleagues (2002b) revealed that the CCP modules of PAPP-A, more specifi-
cally modules CCP3 and CCP4, are involved in the binding of PAPP-A to cell surfaces. 
Preincubation of PAPP-A with glycosaminoglycans (GAG) heparin or heparan sulphate but 
not chondroitin sulphate or dermatan sulphate reduced the binding remarkably. A similar 
effect was seen with pre-treatment of the cells with heparinase. Thus, the cell surface bind-
ing of PAPP-A is most likely mediated through heparan sulphate-like GAGs that are com-
monly found on cell surfaces. The binding is reversible as in the experiments of Laursen 
and colleagues incubation of the cells with heparin after PAPP-A attachment completely 
abrogated binding. Moreover, it was shown that PAPP-A does not have to be synthesized 
in the cell on which it binds.  
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Weyer and colleagues noticed that three clusters of basic residues consisting of positively 
charged Arg and Lys residues are especially important in the interaction between PAPP-A 
and GAGs (Weyer et al., 2004). In the predicted three-dimensional structure of CCP3 and 
CCP4, these clusters form a circular patch of approximately 15 Å of basic residues on the 
surface of CCP3. With two basic residues of CCP4 in the vicinity, the positively charged 
patch mediates the binding to the negatively charged GAGs. (Weyer et al., 2004) 
Evidence of the physiological importance of the surface binding of PAPP-A has been ob-
tained in a study by Conover and colleagues (Conover et al., 2007). Experiments were 
performed with human peripheral monocytes, which were in vitro differentiated and acti-
vated to macrophages, and with active macrophages, which were isolated from atheroscle-
rotic lesions of a rabbit model of atherosclerosis. It was shown that activated macrophages 
bind PAPP-A via GAGs on the cell surface which leads to internalization of PAPP-A by 
these cells. PAPP-A molecules with a mutated CCP3 domain, however, did not bind to or 
become internalized by the macrophages. In another study PAPP-A was found to be asso-
ciated with the membranes of solubilized human trophoblasts of the placenta (Sun et al., 
2002). Interestingly, the affinity of the GAG binding site of PAPP-A seems to be higher for 
heparin than for the GAG on cell surfaces (Weyer et al., 2004).  
Lin-Notch repeat modules 
In the amino acid sequence of PAPP-A three motifs have been identified which are related 
to Lin-Notch repeats (LNR) (Kristensen et al., 1994). These motifs had previously been 
seen in Notch receptors, a group of presumed membrane proteins involved in early tissue 
differentiation. In Notch receptors three LNR motifs are arranged in tandem in the putative 
extracellular part. However, in PAPP-A LNR modules 1 and 2 are found within the prote-
olytic domain (residues 334-360 and 361-393) and LNR 3 is separated from LNR2 by more 
than 1000 amino acids (residues 1478-1503) (Kristensen et al., 1994). The amino acid 
residues conserved between the LNR modules of PAPP-A and Notch receptors have been 
predicted to be involved in calcium coordination based on studies with isolated the Notch 1 
LNR1 module (Boldt et al., 2004) 
The LNR modules of PAPP-A seem to control the substrate specificity of the proteolytic 
activity of PAPP-A, which will be discussed in detail in section 2.2. All LNR modules are 
required for successful PAPP-A mediated cleavage of insulin-like growth factor binding 
protein (IGFBP)-4, but LNR1 and LNR2 are enough for the cleavage of IGFBP-5 (Boldt et 
al., 2004). Recent data from Weyer and colleagues (2007) shows that the LNR3 of one 
PAPP-A subunit interacts with the LNR1 and LNR2 modules of the other PAPP-A subunit 
in the dimer of PAPP-A subunits. This was confirmed by showning that a C-terminal trun-
cated variant of PAPP-A lacking the LNR3 module and a PAPP-A variant mutated at the 
active site can form a functional protease able to cleave IGFBP-4 when co-expressed in 
cells. Moreover, in the structure of the LNR3 module certain charged residues (Asp-1521, 
Arg-1529, Asp-1530) were found to be especially important for the activity (Weyer et al., 
2007). 
Laminin G-like module 
Using secondary structure prediction and sequence alignment, a protein domain was identi-
fied within PAPP-A by Boldt and colleagues (2006) that resembles the laminin G-like (LG) 
modules. These modules are found, for example, in the α-chain of laminin. This module is 
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located in the PAPP-A sequence within the first N-terminal 243 residues and before the 
proteolytic domain. Although the sequence homology with other LG modules is weak, 14 
characteristic β-chains were found in the predicted secondary structure which was sup-
ported by the existence of the disulfide bond between Cys-64 and Cys-155. The LG mod-
ule of PAPP-A was not obvious from the exon structure as the large exon 2 of PAPP-A 
spans most of the LG module and also the first half of the proteolytic domain. However, 
although the module was shown to fold autonomously, it is likely to be required for the 
correct folding of the proteolytic domain. The function of the module is yet unknown but, 
based on the results of Boldt and colleagues (2006), it does not seem to be involved in 
substrate recognition, cell surface binding or complex formation with proMBP. 
Dimerization interface 
As previously mentioned, Cys-1130 is responsible for the covalent dimerization of PAPP-
A monomers (Overgaard et al., 2003). However, amino acids 1064-1098 seem to possibly 
create a non-covalent dimerization interface that enables the activity against IGFBP-4 
without covalent dimerization (Weyer et al., 2007). 
2.1.3 Complexation with proMBP 
Eosinophils, important cells of the immune system, produce a highly cationic protein, ma-
jor basic protein (MBP), which is stored in the granules of eosinophils with other basic 
proteins. These proteins are highly toxic and are released from eosinophils as a defence 
against invading microorganisms and parasites. Moreover, MBP also enhances the immune 
response by activating mast cells and basophils. (Reviewed by Janeway et al., 2005.) 
Popken-Harris and colleagues (1998) showed that in developing eosinophils MBP is pro-
duced as a precursor form, proMBP. The propiece of 90 amino acid residues is highly 
acidic and possibly protects developing eosinophils from damage by the toxic MBP during 
the processing of the uncondensed granules to form mature condensed granules. In mature 
eosinophils only the mature MBP of 117 amino acid residues was found in the condensed 
granules.  
In another study by Popken-Harris and colleagues (1995) it was noticed that unlike mature 
MBP, proMBP is not cytotoxic and not able to stimulate basophil histamine release. More-
over, proMBP inhibited these effects of MBP dose-dependently. The cytotoxic actions of 
MBP may be due to the cationic charge of the protein as it may react with the acidic lipids 
and cause disordering of the lipid cell membranes of the micro-organisms and parasites. 
ProMBP inhibits cytotoxicity probably by neutralizing the basic charge of MBP.  
The group of Popken-Harris (1995) reported that the size of the proMBP polypeptide pre-
dicted from the cDNA sequence is 23.76 kDa. However, they also revealed that the 
propiece of proMBP is highly and variably glycosylated. Thus, proMBP is electrophoreti-
cally extremely heterogeneous with an apparent molecular mass of 30-100 kDa. Overgaard 
and colleagues (1994a) showed that the total carbobydrate content of proMBP is 38.6%. 
They also revealed that proMBP contains one N-bound carbohydrate and several O-bound 
carbohydrate groups as well as at least one O-bound GAG. It is noteworthy that the cova-
lent GAG substitution of proMBP possibly by heparan sulphate at Ser-62 is an unusual 
modification of soluble proteins. 
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Glerup and colleagues (Glerup et al., 2005) reported that upon the formation of the hetero-
tetrameric complex of PAPP-A and proMBP, the status of six cysteines of proMBP sub-
units and two cysteines of PAPP-A subunits change. More specifically, in the process three 
intramolecular disulfide bridges break within proMBP subunits (Cys51/Cys-169, Cys-
89/Cys-189, Cys-104/Cys-107). This leads to the formation of two disulphide bridges be-
tween the proMBP subunits (Cys-104/Cys-104, Cys-107/Cys-107) and two disulphide 
bridges between proMBP and PAPP-A subunits (Cys-169 of proMBP / Cys-652 of PAPP-
A, Cys-51 or proMBP / Cys-381 of PAPP-A). The total redox potential is maintained be-
cause a new bond is formed for every breaking disulfide bond.  
It has been noticed in in vitro studies that the complexation occurs much more efficiently in 
the presence rather than in the absence of cells (Sivanandam et al., 2004; Glerup et al., 
2007). Co-overexpression of PAPP-A and proMBP in cells or co-culture of cells express-
ing PAPP-A or proMBP together leads to rapid production of covalent PAPP-A/proMBP 
complex. On the other hand, incubation of culture medium from PAPP-A producing cells 
and proMBP producing cells together in the absence of the cells results in very slow com-
plexation (Sivanandam et al., 2004; Glerup et al., 2007). 
PAPP-A/proMBP complex shows only very weak binding to the cell surface (Laursen et 
al., 2002b). Moreover, the process of complexation leads to surface detachment of PAPP-A 
(Glerup et al., 2007). Heparinase treated PAPP-A/proMBP binds to cells in a similar man-
ner to PAPP-A dimer implying that the GAG of proMBP probably interacts with the GAG 
binding site of PAPP-A replacing the GAG of the cell surface from the site (Laursen et al., 
2002b). It is noteworthy that both the GAG of proMBP and the formation of covalent 
bonds with PAPP-A are required for the surface detachment of PAPP-A (Glerup et al., 
2007). 
It has been shown that in in vitro conditions in a culture medium without cells and with 
physiological concentrations of PAPP-A (20 nM) and proMBP (200 nM) the complex for-
mation is greatly enhanced by the addition of micromolar concentrations of reductants such 
as glutathione, dithiothreitol or β-mercaptoethanol (Glerup et al., 2005). On the other hand, 
increasing concentrations of NaCl inhibit PAPP-A/proMBP complex formation suggesting 
that ionic interactions are probably important in the complexation process (Glerup et al., 
2007). 
2.2 Activity of PAPP-A 
2.2.1 IGFBP Substrates 
In 1999, PAPP-A as a dimer of PAPP-A subunits was identified as the previously unknown 
insulin-like growth factor (IGF)-dependent IGFBP-4 protease produced by human fibro-
blasts in culture medium (international enzyme code EC 3.4.24.79) (Lawrence et al., 1999). 
Later PAPP-A was also confirmed to be responsible for similar activity in other systems 
such as follicular fluid of various mammals (Mazerbourg et al., 2001), in human pregnancy 
serum (Byun et al., 2001), and in culture medium conditioned by human and porcine coro-
nary artery vascular smooth muscle cells (VSMC) (Bayes-Genis et al., 2001b), luteinizing 
human granulosa cells (Iwashita et al., 1998), cells of mouse osteoblast cell line MC3T3-
E1 (Bunn et al., 2004), bovine mammary fibroblast cells (Fleming et al., 2005), human 
trophoblast and decidualized endometrial stromal cells (Giudice et al., 2002) and human 
osteoblasts (Qin et al., 2000). In addition to IGFBP-4, PAPP-A has also been shown to 
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degrade IGFBP-5 (Laursen et al., 2001; Rivera and Fortune, 2003b) and IGFBP-2 (Monget 
et al., 2003; Gerard et al., 2004; Kumar et al., 2005).  
IGFs and IGFBPs 
IGF-I and -II are single-chain polypeptides (~7.5 kDa) that function as peptide hormones. 
They share homology with both themselves and insulin. IGFs are important regulators of 
various cell functions as they, for example, stimulate protein synthesis, promote migration, 
enhance proliferation and inhibit apoptosis. Circulating IGFs are primarily produced by the 
liver. However, IGF expression has also been found locally in most tissues all over the 
body. IGFs interact with their cell membrane-associated receptors, namely type I and type 
II IGF receptors. Type I IGF receptor (IGF-R1) is homologous to the insulin receptor and 
has tyrosine kinase activity. Importantly, IGF-R1 is responsible for IGF-I and IGF-II in-
duced intracellular signalling. Type II IGF receptor, also known as mannose-6-phosphate 
receptor, is not structurally related to IGF-R1, has no known intracellular signalling actions 
and possibly just mediates the clearance of IGF-II. (For reviews, see Donnelly and Holly, 
1996; Le Roith, 1997; Bayes-Genis et al., 2000; Delafontaine et al., 2004; Holly and Perks, 
2006; Beattie et al., 2008.) 
The interaction of IGFs with the receptors is regulated by six IGFBPs (IGFBP1-6) of the 
size of 22-30 kDa, which bind IGFs with high affinity, even higher than that of IGF I re-
ceptor. The affinity constants for this interaction are shown in Table 1, a lower KD value 
reflecting higher affinity. The expression of different IGFBPs is tissue-specific and devel-
opmental stage-specific. Thus, the concentrations of IGFBPs vary in different body com-
partments. The IGFBPs function as extra-cellular storage pools for IGFs by increasing the 
half-life of IGFs and modulating the availability of IGFs in tissues. In the circulation more 
than 95% of the IGFs is bound with IGFBP-3 in a complex that also includes an additional 
large protein, acid-labile subunit. When IGF leaves this complex, it may enter tissues in 
other complexes with other IGFBPs. In addition to IGF binding, the IGFBPs may also have 
IGF-independent functions such as stimulation of the VSMC migration by IGFBP-5. (For 
reviews, see Donnelly and Holly, 1996; Le Roith, 1997; Bayes-Genis et al., 2000; Delafon-
taine et al., 2004; Holly and Perks, 2006; Beattie et al., 2008.) 
Table 1. Equilibrium affinity constants of the interactions of the receptor, binding proteins and binding 






 IGF-I IGF-II Reference  
IGF-R1 4.45 23 Beattie et al. 2008 
IGFBP-1 0.8 0.33 Laursen et al. 2007 
IGFBP-2 0.36 0.11 Laursen et al. 2007 
IGFBP-3 0.32 0.16 Laursen et al. 2007 
IGFBP-4 0.27 0.18 Laursen et al. 2007 
IGFBP-5 0.48 0.23 Laursen et al. 2007 
IGFBP-6 2.6 0.14 Laursen et al. 2007 
IGFBP-4 fragments     
     N-terminal 4.5 0.2 Beattie et al. 2008 
     C-terminal NDa 216 Beattie et al. 2008 
IGFBP-5 fragments     
     N-terminal 49 7 Beattie et al. 2008 
     C-terminal 21 183 Beattie et al. 2008 
a KD not determined because of too slow reaction  
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The IGF binding of IGFBPs is mediated by conserved amino acid residues of the N-
terminal part and the C-terminal part of the binding protein (Fig. 2). For example, an N-
terminal sequence spanning the area between Lys-67 and Cys-79 in IGFBP-4 seems im-
perative for IGF binding. In the C-terminal part of IGFBP-4 the sequence located between 
the residues Cys-205 and Val-214 including the conserved sequence of Cys-Tyr-Cys-Val-
Asp is also important by facilitating IGF binding (Qin et al., 1998; Beattie et al., 2008).  
 
 
Figure 2. A) The general structure of IGFBP-2, -4 and -5 with the areas involved in the IGF binding indi-
cated (N, N-terminal IGF-binding sequence; C, C-terminal IGF-binding sequence; HB, highly basic hepa-
rin binding sequence). B) The amino acid sequences of the sites where PAPP-A cleaves IGFBP-2, -4 and  
-5 and the autocleavage site of PAPP-A. The basic residues are in bold and the lysine located 16 residues 
N-terminal from the scissile bond is underlined. 
Beattie and colleagues (2008) have studied the interaction of IGFBP-5 with heparin. 
IGFBP-5 is able to interact with cell surface and extracellular matrix proteoglycans by 
binding to heparan sulphate moieties although IGFBP-2 and IGFBP-4 do not bind heparan 
sulphate. The amino acid residues mediating this interaction are located in the C-terminal 
part of the protein at the highly basic heparin binding sequence between Arg-201 and Arg-
218 (Fig. 2). Interestingly, this sequence also appears to be important for high affinity bind-
ing of IGFs with IGFBP-5 even though it is not found in IGFBP-4. Moreover, in in vitro 
studies by Beattie and colleagues (Beattie et al., 2008), IGFs were shown to mediate the 
detachment of IGFBP-5 from heparin, which is in line with the IGFBP-5 release from the 
cell surface by IGF.  
Proteolysis of IGFBPs by PAPP-A 
Signalling through the IGF axis is regulated by proteases which degrade IGFBPs. In all 
systems studied PAPP-A seems be the predominant if not the only IGFBP-4 protease 
(Overgaard et al., 2000; Rivera and Fortune, 2003a). However, of the substrates of PAPP-
A, there are other proteases at least for IGFBP-5 (Bayes-Genis et al., 2001b). As previously 
stated, the PAPP-A dimer binds to cell surfaces through a GAG found on the cell surface. 
Cell surface bound PAPP-A is active and hence the GAG binding directs the PAPP-A me-
diated release of free IGFs to the vicinity of the IGF receptors present on the cell surface 







CLQ HFA I D STSGG M  VNGAPK K R R     K K
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SGM ELAVF E VTEQH Q MG GGK R K     R   K  KIGFBP-2
IGFBP-4
IGFBP-5
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Figure 3. The role of PAPP-A in the IGF signalling axis. A) The free IGF-I and -II molecules are bound 
by IGFBP-2, -4 and -5. B) PAPP-A dimer attached to a cell surface glycosaminoglycan cleaves the IGFBP 
and thus releases IGF to interact with type I IGF receptor (IGF-R1). C) ProMBP subunits form a covalent 
complex with the PAPP-A dimer which leads to inactivation of PAPP-A and detachment from the surface. 
The fragments of cleaved IGFBP-4 and -5 also have some affinity for IGFs that limits, to 
some extent, the interaction of IGFs with their receptors (Laursen et al., 2007). The first 
findings on this matter considered the affinity of IGFBP-4 fragments, which seemed to be 
higher for IGF-II than IGF-I (Smith et al., 2001). Later more detailed studies followed 
reporting the affinity values between IGF-I and IGF-II and the cleavage products of both 
IGFBP-4 and IGFBP-5 and confirmed these findings (Table 1) (Laursen et al., 2007). In-
terestingly, unlike what is seen with IGFBP-4, the degradation fragments of IGFBP-5 ap-
pear to interact cooperatively with IGFs. This leads to more pronounced inhibition of re-
ceptor activation with the combination of N-terminal and C-terminal fragments than with 
one of the fragments alone (Laursen et al., 2007). 
PAPP-A cleaves IGFBP-4 within the variable mid-region between Met-135 and Lys-136 
(Fig. 2) (Chelius et al., 2000; Qin et al., 2000; Laursen et al., 2002a). This cleavage site 
seems to be conserved between mammals (Chelius et al., 2000). Mutations of basic resi-
dues at or near the cleavage site of IGFBP-4 (Lys-134, Lys-136) inhibit degradation (Bunn 
et al., 2004). However, basic residues distant from the scissile bond of IGFBP-4 (Lys-120, 
Arg-126, Arg-128) are also important for cleavage (Laursen et al., 2002a). The efficient 
degradation of an IGFBP-4 derived peptide requires at least 16-17 residues on the N-
terminal side of the cleavage site (Laursen et al., 2002a). Interaction between IGF (IGF-I or 
-II) and IGFBP-4 is essential for degradation activity (Qin et al., 2000; Gyrup and Oxvig, 
2007). Very slow IGFBP-4 degradation can be seen in the absence of IGFs but the activity 
of the protease is significantly enhanced by the presence of IGF-I or IGF-II (Overgaard et 
al., 2000; Boldt et al., 2001; Byun et al., 2001; Laursen et al., 2001; Bunn et al., 2004; 
Gyrup and Oxvig, 2007). Importantly, it has been shown that IGF does not function as a 
cofactor of PAPP-A but rather binds to IGFBP-4 making it a better substrate for PAPP-A 
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IGFBP-5 is cleaved by PAPP-A between Ser-143 and Lys-144 (Fig. 2) (Laursen et al., 
2001; Laursen et al., 2002a). In IGFBP-5, basic residues are found in similar positions 
relative to the scissile bond as in IGFBP-4 (Laursen et al., 2002a). However, only Lys-128 
located 16 residues from the scissile bond is important for cleavage (Laursen et al., 2002a). 
The cleavage of IGFBP-5 is not dependent on IGFs but is slightly inhibited by them 
(Gyrup and Oxvig, 2007). In the presence of IGF-II the cleavage rates of IGFBP-4 and 
IGFBP-5 by PAPP-A are similar, while IGFBP-5 without IGFs seems to be the best sub-
strate for PAPP-A (Laursen et al., 2001; Gyrup and Oxvig, 2007).  
PAPP-A cleaves IGFBP-2 between Gln-165 and Met-166 (Fig. 2) (Monget et al., 2003; 
Gerard et al., 2004). The degradation is dependent on IGF dose and more IGFs are needed 
for efficient cleavage than with IGFBP-4 (Monget et al., 2003; Gyrup and Oxvig, 2007). 
Thus, similarly as IGFBP-4, IGFBP-2 probably undergoes conformational change upon 
IGF binding which makes it a better substrate for PAPP-A. However, IGFBP-2 is less sen-
sitive to proteolysis by PAPP-A than IGFBP-4 and the cleavage reaction is notably slower 
with IGFBP-2 (Monget et al., 2003; Gyrup and Oxvig, 2007). The effect of the basic resi-
dues of IGFBP-2 on cleavage efficiency of PAPP-A has not been studied. However, Lys 
located 16 residues from the scissile bond important in the degradation of IGFBP-4 and 
IGFBP-5 is also found in IGFBP-2 (Fig. 2).  
2.2.2 Other substrates 
In addition to degradation of IGFBP-2, -4 and -5, PAPP-A has been shown to be capable of 
autocleavage. Boldt and colleagues (2001) noticed that cultivation of cells producing re-
combinant wild-type PAPP-A in serum-free medium resulted in pronounced (>90%) auto-
cleavage of PAPP-A. The extent of autocleavage was associated with the length of the 
incubation. However, in serum-containing medium the autolysis was only limited (< 5%). 
It was shown that due to autocleavage, the PAPP-A monomer of 200 kDa was turned into a 
50 kDa N-terminal fragment and a 150 kDa C-terminal fragment. The cleavage site was 
found between Phe-386 and Asn-387 at the C-terminal end of the LNR2 within the prote-
olytic domain. Thus, the cleavage site is in close vicinity to the Cys-381 involved in the 
complexation with proMBP. Near the cleavage sites of IGFBP-4 and -5 and the autocleav-
age site of PAPP-A a basic residue is found in all only at position -16 which seems to be 
important for cleavage activity (Fig. 2) (Laursen et al., 2002a). 
After PAPP-A finding of 1974, other activities for this protein have also been suggested 
including degradation of other proteins or inhibition of other proteases. However, these 
conclusions arose probably due to inefficient purification of PAPP-A, complexation with 
proMBP that was still unknown and the reactivity of polyclonal anti-PAPP-A sera with 
proMBP, use of conditions divergent from the physiological situation or inaccurate predic-
tion of function from structure. For example, it has been shown that PAPP-A derived from 
pregnancy serum can inhibit human leukocyte elastase and human cathepsin G (Sinosich 
and Zakher, 1991; Oxvig et al., 1994b). However, this is seen only at an ionic strength 
significantly lower than the physiological concentration and the inhibition is most likely 
due to interactions with the GAG moiety of proMBP (Oxvig et al., 1994b).  
Another example is linked to the complement cascade of the immune system. Bischof and 
colleagues (1984) showed that PAPP-A inhibited complement-induced haemolysis and that 
this phenomenon was a result of direct interaction with complement C3. However, in this 
study PAPP-A was purified from third trimester pregnancy heparin plasma or with heparin 
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affinity column from ethylenediaminetetraacetic acid (EDTA) anticoagulated plasma. This 
provided the possibility of contamination with heparin, a potent complement inhibitor. In 
the same study experiments were also conducted with unpurified PAPP-A in pregnancy 
plasma in which labelled C3 was found to bind to PAPP-A that was captured by rabbit anti-
PAPP-A antibodies. However, this polyclonal PAPP-A antisera was produced with PAPP-
A purified from pregnancy serum i.e. PAPP-A/proMBP complex used as the antigen and 
probably also had anti-proMBP reactivity. Another group has later shown that complexes 
form in serum between proMBP and C3-derived C3dg (Christiansen et al., 2000). Thus, in 
the study of Bischof and colleagues interaction between C3 and proMBP could have been 
possible instead of interaction between PAPP-A and C3.  
There have been some suggestions that PAPP-A might modulate immune reactions. How-
ever, the evidence published on this matter in international peer-reviewed journals is scarce 
and contradictory. For instance, PAPP-A has been suggested to have an effect on the spon-
taneous proliferation of peripheral blood polymorphonuclear cells. However, the effect 
seems to change from suppressive to stimulation depending on the dose of PAPP-A as well 
as the gender and age of the donors or the phase of pregnancy. (Reviewed by Zhabin et al., 
2003.) 
Despite the fact that the sequence of the active site of PAPP-A is almost identical with that 
of matrix metalloproteinases, to date there is no published evidence that PAPP-A would 
degrade structural matrix proteins.  
The enzyme activities of the proteins that resemble PAPP-A have also been studied. 
Ulilysin shows similar pattern of IGF-modulated proteolysis of IGFBP-4 suggesting that 
conserved structural features in the proteolytic domain are responsible for substrate recog-
nition (Gyrup and Oxvig, 2007). However, in addition to IGFBP-2, -4 and -5, ulilysin is 
also able to cleave various other substrates such as IGFBP-3, IGFBP-6, insulin β chain, 
azoalbumin, gelatine, actin and elastin and itself for autoactivation of the inactive proform 
proulilysin (Tallant et al., 2006; Tallant et al., 2007). The splice variant of PAPP-A found 
in mice, PAPP-Ai, degrades IGFBP-5 IGF-independently in a similar manner to PAPP-A, 
but the IGF-dependent IGFBP-4 degradation is highly reduced, possibly due to the positive 
charge of the insert (Soe et al., 2002; Bunn et al., 2004). PAPP-A2, which does not bind to 
cell surfaces (Laursen et al., 2002b) due to three basic residues of the CCP3 module re-
placed by acidic residues (Weyer et al., 2004), degrades IGFBP-5 IGF-independently simi-
lar to PAPP-A but does not cleave IGFBP-4 even in the presence of IGF-II (Overgaard et 
al., 2001).  
2.2.3 Activity regulation 
Inhibition by proMBP 
ProMBP has been identified as an inhibitor of the proteolytic activity of PAPP-A 
(Overgaard et al., 2000; Chen et al., 2002). Inhibition of the proteolytic activity of PAPP-A 
by proMBP requires covalent bonding, as proMBP which lacks Cys-51 and Cys-169, the 
residues responsible for PAPP-A – proMBP intermolecular disulphide bridges, does not 
cause inhibition (Overgaard et al., 2004). Apparently, this is the only known example of a 
case in which inhibition of enzyme activity is mediated through covalent disulfide bridges 
between the enzyme and the inhibitor (Glerup et al., 2005). 
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The actual mechanism of the inhibition of PAPP-A activity by proMBP is still unknown. 
The complexation may abrogate the access of the substrate to the active site of PAPP-A or 
induce a conformational change leading to inactivation (Overgaard et al., 2004). Moreover, 
substrate-like interactions of the basic portion of proMBP may interfere with the binding of 
the substrate to PAPP-A (Laursen et al., 2002a). Notably, one of the residues of PAPP-A 
involved in the complexation with proMBP, Cys-381, lies within the proteolytic domain of 
PAPP-A (Overgaard et al., 2003). However, results of the study by Overgaard and col-
leagues (2004) imply that the cysteine residues of proMBP do not interact directly with the 
zinc atom of the active site of PAPP-A. 
Overgaard and colleagues (2000) found that in late pregnancy serum the vast majority of 
PAPP-A is present in the complexed inactive form. The activity of recombinant PAPP-A 
dimer is 100-fold higher than that of PAPP-A purified from pregnancy serum or the activ-
ity in unpurified late pregnancy serum. However, in pregnancy serum some residual activ-
ity is still detectable and it is assumed to be caused by a minor fraction (<1%) of uncom-
plexed PAPP-A. Interestingly, pregnancy serum derived PAPP-A/proMBP complex sepa-
rated from uncomplexed PAPP-A still shows some very low activity. This is possibly due 
to the presence of a minor subpopulation of partly inhibited PAPP-A in a 2:1 complex with 
proMBP or the incomplete inhibitory effect of proMBP. 
A protein activator of PAPP-A that forms a covalent complex with PAPP-A has been sug-
gested in one study by Sivanandam and colleagues (2004b). Human skin fibroblasts and 
human osteoblasts were treated with a phorbol ester tumor promoter acting as protein 
kinase C activator, phorbol 12-myristate-13-acetate (PMA). This reduced IGFBP-4 prote-
olysis without significantly decreasing the PAPP-A level in the culture medium. However, 
production of proMBP was not induced. SDS-PAGE analyses implied that PAPP-A was 
expressed in normal conditions by fibroblasts as a 470 kDa active complex with a protein 
other than proMBP. It was suggested that PMA reduced the synthesis or increased the deg-
radation of this protein and thus induced conversion of PAPP-A to a less active ~400 kDa 
form. However, to date neither the members of this group nor other groups have published 
anything further on this mysterious protein activator.  
Common protease inhibitors and optimal conditions 
Of the common inhibitors of proteases the activity of PAPP-A against IGFBPs has been 
shown to be inhibited only by 1,10-phenanthroline (a specific chelator of zinc ions) and 
EDTA (a chelator of divalent cations) (Chandrasekher et al., 1995; Besnard et al., 1996; 
Besnard et al., 1997; Mazerbourg et al., 2000; Overgaard et al., 2000; Mazerbourg et al., 
2001; Rivera and Fortune, 2001; Rivera and Fortune, 2003b; Gerard et al., 2004). The ac-
tivity of PAPP-A is not inhibited by phenylmethylsulfonyl fluoride (an inhibitor of serine 
proteases), pepstatin A (an inhibitor of aspartic proteases), E64 (a highly specific inhibitor 
of cysteine proteases), aprotinin (a serine protease inhibitor), benzamide (a serine protease 
inhibitor), phosphoramidon (an inhibitor of endopeptidases), bestatin (an inhibitor of amin-
opeptidases), tissue inhibitor of metalloproteinase-1 and -2 (natural inhibitors of matrix 
metalloproteinases), B-2116 (a synthetic inhibitor of matrix metalloproteinases) and leu-
peptin (an inhibitor of trypsin-like serine and some cysteine proteases) (Chandrasekher et 
al., 1995; Besnard et al., 1996; Besnard et al., 1997; Mazerbourg et al., 2000; Overgaard et 
al., 2000; Mazerbourg et al., 2001; Rivera and Fortune, 2003b; Gerard et al., 2004).  
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After inhibition caused by EDTA, activity was restored by the addition of calcium chloride 
and zinc chloride while zinc chloride alone was sufficient to restore activity after 1,10-
phenanthroline-induced inhibition. Thus, before any detailed structural data was available, 
PAPP-A was classified as a calcium- and zinc-dependent metalloprotease (Besnard et al., 
1996). Interestingly, only the proteolytic activity of PAPP-A against IGFBP-4 is dependent 
on calcium while calcium is not required for the degradation of IGFBP-5 (Besnard et al., 
1996; Besnard et al., 1997; Boldt et al., 2004). Activity increases in in vitro conditions with 
increasing Ca2+ concentration until the concentration of 1 mM is reached, but even very 
low trace amounts (<6 µM) are enough for detectable activity (Boldt et al., 2004). The 
dependence on calcium may be related to the binding of calcium by the LNR3 motif as this 
motif is required for IGFBP-4 degradation but not for IGFBP-5 degradation (Boldt et al., 
2004). 
Even though as a protease PAPP-A is dependent on zinc, it was unexpectedly shown that 
high zinc chloride concentration completely inhibits activity (Besnard et al., 1996; Besnard 
et al., 1997). When optimal conditions for PAPP-A activity measurements were determined 
by Laursen and colleagues (2002a) with wild-type recombinant protein, it was noticed that 
an added Zn2+ concentration as low as 5 µM inhibited activity to some extent and 50 µM 
almost completely blocked the degradation reaction. As a possible explanation for this 
phenomenon it was suggested that high zinc concentration leads to the binding of another 
zinc ion close to the active site, which has been seen with thermolysin.  
Surprisingly, NaCl at physiological concentration was also found deleterious for the de-
grading activity of PAPP-A in in vitro experiments (Laursen et al., 2002b; Gyrup et al., 
2007). A NaCl concentration of 100 mM led to a 65% decrease in activity compared to the 
reaction without additional NaCl (Laursen et al., 2002a). This implies that the substrate 
binding possibly depends on interactions between charged residues (Gyrup et al., 2007). 
The pH optimum of PAPP-A in natural materials has been shown to lie between 7.4-7.6 
(Mazerbourg et al., 2000; Mazerbourg et al., 2001; Gerard et al., 2004). In in vitro studies 
with recombinant human PAPP-A, Laursen and colleagues (2002a) found the pH optimum 
for activity at pH 8. They also showed that when the pH was decreased from neutral to 
acidic, the activity of PAPP-A decreased quickly leading to complete abrogation of the 
activity at pH 6. Protonation of His residues and subsequent loss of zinc ion at the active 
site was suggested as a possible explanation for this. 
Inhibition by IGFBPs 
As the cleavage of IGFBP-4 is dependent on the binding of IGF, other IGFBPs seem to be 
able to inhibit the activity of PAPP-A against IGFBP-4 indirectly by sequestering the 
available IGFs. Accordingly, in a study by Fowlkes and colleagues (1997), IGFBP-3, -5 
and -6 inhibited IGFBP-4 degradation in MC3T3-E1 murine osteoblast conditioned cell 
culture medium. The inhibitory effect was reversed by the addition of IGFs. As IGFBP-5 
without IGFs is the best substrate for PAPP-A and the degradation of IGFBP-4 is IGF-
dependent, in low concentration of IGFs PAPP-A preferably cleaves IGFBP-5 first and 
IGFBP-4 degradation takes place only after the local IGF concentration is high enough 
(Laursen et al., 2007). Being the worst substrate, IGFBP-2 is degraded last (Smith et al., 
2001). 
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Inhibition by heparin binding peptides 
It has been noticed that certain basic heparin binding peptides inhibit the activity of PAPP-
A (Fowlkes et al., 1997; Mazerbourg et al., 2000; Mazerbourg et al., 2001). Synthetic pep-
tides, which contain the highly basic (calculated pI >10) C-terminal regions of IGFBP-3, -5 
and -6 including the heparin-binding sequence XBBBXXBX, inhibit the IGFBP-4 degrad-
ing activity of PAPP-A. However, the homologous yet neutral (calculated pI 6.9) IGFBP-4 
peptide does not cause inhibition. Heparin addition reverses such inhibitory effects. Other 
studies have shown that heparin-binding domain peptides derived from IGFBP-5, IGFBP-
3, vitronectin or heparin/heparan sulfate –interacting protein (HIP) inhibit the IGFBP-2 
degradation by PAPP-A (Mazerbourg et al., 2003; Gerard et al., 2004). IGFBP-5 derived 
heparin binding peptide P5 inhibited dose-dependently the cleavage of IGFBP-2 by PAPP-
A and showed high affinity to PAPP-A (KD: 3.85 x 10
-11) (Monget et al., 2003). Moreover, 
a peptide containing the highly basic heparin-binding consensus sequence of C-terminal 
IGFBP-3 inhibited PAPP-A activity against IGFBP-4 as efficiently as EDTA (Bunn et al., 
2004). The inhibition mechanism possibly involves competition to prevent substrate bind-
ing (Laursen et al., 2002a). 
Inhibition by antibodies 
Antibodies may also inhibit the activity of PAPP-A. Polyclonal antibodies created against 
the PAPP-A/proMBP complex have been shown to inhibit the cleavage of IGFBP-4 by 
human recombinant PAPP-A (Overgaard et al., 2000). In fact, such polyclonal antibodies 
were widely used when PAPP-A was identified as the IGFBP protease in several systems 
by immunodepletion and immunoinhibition (Qin et al., 2000; Bayes-Genis et al., 2001b; 
Byun et al., 2001; Mazerbourg et al., 2001; Giudice et al., 2002; Bunn et al., 2004; Flem-
ing et al., 2005).  
Furthermore, monoclonal antibodies have also been developed to specifically abrogate the 
activity of PAPP-A. An inhibitory antibody that presumably binds the active site of PAPP-
A was created by Chen and colleagues (2007). The phage display technique was utilized 
with wild-type biotinylated PAPP-A used for positive selection and the inactive PAPP-A 
mutant E483A for negative selection. The IgG antibody created from the Fab-phage fusion 
inhibited the degradation of an IGFBP-4 derived peptide by PAPP-A with an inhibitory 
constant Ki of  0.7 nM. Mikkelsen and colleagues (2008) generated a monoclonal phage-
derived single-chain variable fragment antibody which inhibits the activity of PAPP-A 
against IGFBP-4 but not against IGFBP-2 or IGFBP-5. A C-terminal fragment (amino acid 
residues 1133-1547) of PAPP-A was used for screening. The selective inhibition was 
achieved through antibody binding to the LNR3 module. The presence of calcium was 
crucial for the binding of the antibody, which supports the assumption that this module 
binds calcium. The antibody inhibited the activity of PAPP-A against native IGFBP-4 with 
an inhibitory constant Ki of 1.2 nM while the cleavage of an IGFBP-4 derived peptide was 
not inhibited.  
2.3 Expression and physiological effects of PAPP-A 
In early studies the expression of PAPP-A in different tissues was investigated with poly-
clonal antibodies that were generated using PAPP-A purified from pregnancy serum as the 
antigen (reviewed by Rosen, 1986). However, after it was realized that PAPP-A in late 
pregnancy serum is a complex of PAPP-A and proMBP, it was confirmed that such poly-
clonal antibodies also bind proMBP and MBP (Oxvig et al., 1993). Moreover, cross-
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reactivities for other molecules such as haptoglobin were also reported for certain poly-
clonal antibody products that were used in the early studies (Bueler and Bersinger, 1989). 
Thus, the results of the early studies are not reliable because where PAPP-A was found 
there could have actually been other molecules containing proMBP or MBP or even other 
non-related cross-reactants. More reliable results of the presence and expression of PAPP-
A in certain tissues have been obtained with studies analysing the expression of PAPP-A 
mRNA, the activity of PAPP-A (which seems to be PAPP-A specific in the case of IGFBP-
4 degrading activity) and immunoreactivity with antibodies binding only to the PAPP-A 
subunit. 
In a study by Overgaard and colleagues (1999) the expression of PAPP-A and proMBP 
mRNA was detected by a reverse transcription polymerase chain reaction (RT-PCR) 
method in all tested human tissues including female reproductive tissues (ovary, tuba, uter-
ine, endometrium, and myometrium from postmenopausal women) and in nonreproductive 
tissues (kidney, colon, prostate, prostate carcinoma, bone marrow cells, breast, and breast 
carcinoma). However, the expression of both proteins was at least 200-fold higher in late 
pregnancy placenta than in the other tissues studied. Furthermore, in first trimester placenta 
the expression was significantly lower than in late pregnancy placenta. PAPP-A mRNA 
expression has also been reported in the human brain (Haaning et al., 1996). In mice 
PAPP-A mRNA expression was detected by Hourvitz and colleagues (2002) by the RT-
PCR method especially in testis, kidney, breast and embryo tissues but also in brain, heart, 
spleen, skin, muscle, gastrointestinal tract, ovary prostate and uterus tissues. PAPP-A 
mRNA was not found in the murine thymus, liver, lung and adrenal gland.  
The expression of PAPP-A is regulated differently in different cells and also in the cells of 
the same type from individuals of different ages. For instance, PAPP-A expression in 
smooth muscle cells is higher in adult rats than in neonatal rats (Smith et al., 2001). How-
ever, similarities are also naturally seen. For instance, tumor necrosis factor-α (TNFα) and 
interleukin (IL)-1β seem to stimulate PAPP-A expression in many cell types studied 
(Conover et al., 2004b; Resch et al., 2004; Conover et al., 2006; Resch et al., 2006a; 
Conover et al., 2008a). The effects of various agents on PAPP-A expression in different 
cell types are summarized in Table 2. 
Some insight into the physiological role of PAPP-A in vivo have been provided by studies 
investigating mice with knocked-out PAPP-A genes (PAPP-A KO). Conover and col-
leagues (2004a) reported that homozygous PAPP-A KO mice are viable but only 60% of 
the size of wild-type mice at birth and they remain 40% smaller during postnatal develop-
ment. Thus, PAPP-A seems to be an essential growth regulator. Dwarfism is proportional, 
the organ-to-body weight ratios are normal. However, the PAPP-A KO mice are otherwise 
normal and fertile. Mice heterozygous for PAPP-A KO do not differ in size from wild-type 
mice (Conover et al., 2004a). The phenotype of the homozygous PAPP-A KO mouse is 
strikingly similar to the IGF-II KO mouse (Conover et al., 2004a). Interestingly, a growth 
deficit, even though not as severe as seen in PAPP-A KO mice, also affects homozygous 
IGFBP-4 KO mice (Ning et al., 2008). However, this growth-deficit is completely restored 
in double IGFBP-4/PAPPA KO mice. 
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Table 2. The effect of various agents on PAPP-A expression by cells in cell culture conditions. 
Agent   Stimulationa,b Suppressiona,b No effecta,b References 
BFGF basic fibroblast 
growth factor 
- - OB, dermal FB Conover et al. 2004b, 







cell line JAR 
- - Haaning et al. 1996 
Bikunin - - Ovarian cancer 
cell line HRA 




OB - Coronary artery EC Jadlowiec et al. 2005, 











cell line U87MG 
- - Moreno et al. 2006 
DM dexamethasone - - OB Conover et al. 2004b 
βE2 β-estradiol - - OB Conover et al. 2004b 
EGF epidermal growth 
factor  
- - Coronary artery EC, 
OB, dermal FB 
Conover et al. 2004b, 
Resch et al. 2004,   
Conover et al. 2008a 
FGF fibroblast growth 
factor 
- - Coronary artery EC Conover et al. 2008a 
Forskolin - OB - - Conover et al. 2004b 




brane GC (rat) 
- - Iwashita et al. 1998, 
Matsui et al. 2004 
IFNγ interferon-γ  - Dermal FB - Resch et al. 2004 
IGF-I insulin-like growth 
factor-I 
- - Coronary artery EC, 
OB 
Conover et al. 2004b, 
Conover et al. 2008a 
IGF-II insulin-like growth 
factor-II 
- - OB Conover et al. 2004b 
IL-1β interleukin-1β Coronary artery 
SMC, coronary 
artery EC, OB, 
dermal FB 
- Peripheral blood 
MC, acute mono-
cyteic leukaemia 
cell line THP-1 
Conover et al. 2004b, 
Resch et al. 2004,  
Conover et al. 2006, 
Resch et al. 2006a, 
Conover et al. 2007, 
Conover et al. 2008a 
IL-4 interleukin-4 OB - - Conover et al. 2004b 
IL-6 interleukin-6 Coronary artery 
SMC 
- Coronary artery EC, 
OB 
Conover et al. 2004b, 
Conover et al. 2008a 
IL-13 interleukin-13 - - OB Conover et al. 2004b 
Insulin - - - Coronary artery EC Conover et al. 2008a 
LDL low-density 
lipoprotein 
- - Coronary artery EC,       
coronary artery 
SMC 
Conover et al. 2008a 
MCSF macrophage colony 
stimulating factor 
- - Acute monocyteic      
leukaemia cell line 
THP-1, peripheral 
blood MC 
Conover et al. 2007 
OSM oncostatin M - - OB Conover et al. 2004b 
oxLDL oxidised low-
density lipoprotein 
- - Coronary artery EC, 
coronary artery 
SMC 
Conover et al. 2008a 
PDGF platelet-derived 
growth factor 
- - Dermal FB Resch et al. 2004 
PG E2 prostaglandin E2  OB - - Conover et al. 2004b 
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(continued from previous page) 




- - Peripheral blood MC, 
acute monocyteic 
leukaemia cell line 
THP-1 
Conover et al. 2007 




GC (rat, mouse), 
luteinizing GC 
(mouse) 
- Cumulus GC (mouse, 
rat) 
Hourvitz et al. 2002, 
Matsui et al. 2004 
PTH parathyroid 
hormone 




OB - Coronary artery EC Ortiz et al. 2003, 
Conover et al. 2004b, 








artery EC, OB, 
dermal FB 
- - Conover et al. 2004b, 
Resch et al. 2004, 
Conover et al. 2006, 
Resch et al. 2006a, 
Conover et al. 2008a 
aAll cells were human derived unless otherwise stated 
bAbbreviations: EC, endothelial cells; FB, fibroblasts; GC, granulosa cells; MC, monocytes; OB, osteoblasts; SMC, 
smooth muscle cells 
Fibroblasts derived from PAPP-A deficient mouse embryos completely lack IGFBP-4 pro-
teolytic activity, confirming PAPP-A as the IGFBP-4 protease in this system (Conover et 
al., 2004a). Moreover, there is significantly more IGFBP-4 in adult serum of PAPP-A KO 
homozygote mice than in wild-type littermates (Ning et al., 2008).  
In addition to dwarfism, the genetic deletion of PAPP-A in mice leads to a 30-40% increase 
in lifespan (Conover and Bale, 2007). Fasting glucose and insulin, food intake or energy 
expenditure of aged, 18-month-old mice do not differ significantly between PAPP-A KO 
and wild-type mice when the smaller body weight of PAPP-A KO mice is taken into ac-
count (Conover et al., 2008b). Thus, the ‘rate of living’ or an ‘altered glucose-insulin sys-
tem’ do not seem to be valid explanations for the longevity of PAPP-A KO mice.  
The function of PAPP-A in many systems is not yet fully understood. However, the role of 
PAPP-A seems to be related to the enhancement of the activities of IGF by degradation of 
IGFBPs (Byun et al., 2001; Resch et al., 2004; Qin et al., 2006b). What is known about 
PAPP-A and its expression and role in certain physiological and pathological processes 
will be discussed in the following sections. 
2.3.1 Pregnancy 
As previously stated, PAPP-A was first found in 1974 in the third-trimester plasma of 
pregnant women (Lin et al., 1974). In the late 1970s and early 1980s PAPP-A was local-
ized with immunohistochemical techniques in the syncytiotrophoblasts of the placenta and 
also in the decidua of the uterus (Fig. 4) (reviewed by Rosen, 1986). However, these early 
studies may have been inaccurate due to the use of polyclonal PAPP-A antibodies that were 
also reactive with proMBP and possibly some other proteins (Bueler and Bersinger, 1989; 
Oxvig et al., 1993). Importantly, proMBP is also expressed in the placenta (Bonno et al., 
1994) and it is found in serum throughout pregnancy in 4- to 10-fold molar excess com-
pared to PAPP-A because proMBP is found also in other protein complexes (Oxvig et al., 
1995).  
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Figure 4. The structure of the placenta. A) The chorionic villi float in the interstitial space filled with 
maternal blood from which nutrients and oxygen are transferred through the syncytiotrophoblast (st) and 
villous cytotrophoblast (vct) layers to the capillaries (c). The capillaries transfer the nutrients and oxygen 
to the fetus through the umbilical cord. B) The anchoring villi are attached to the maternal decidua by 
extravillous trophoblasts (et) which also invade and transform the maternal uterine spiral arteries to enable 
and increase the flow of maternal blood to the interstitial space. PAPP-A protein has been found in the 
placenta in the septa, acnchoring villi and the syncytiotrophoblasts of chorionic villi while PAPP-A 
mRNA has been found in the syncytiotrophoblasts and in the extravillous trophoblasts (Bonno et al., 
1994). 
With mRNA expression studies it was confirmed, without antibody specificity doubts, that 
in human tissues PAPP-A expression is the highest in the placenta (Overgaard et al., 1999). 
Moreover, PAPP-A mRNA expression in total placental extracts increases during the 
course of pregnancy (Guibourdenche et al., 2003). With immunohistochemical staining 
using PAPP-A specific antibodies that do not bind proMBP, PAPP-A protein was found to 
localize within the placenta in the placental septa formed of maternal decidua, in the an-
choring villi, and in the syncytiotrophoblasts of the chorionic villi (Fig. 2) (Bonno et al., 
1994). With in situ hybridization PAPP-A mRNA expression was detected in the syncyti-
otrophoblasts and the placental X cells, i.e. the extravillous trophoblasts (Bonno et al., 
1994). In contrast, with immunohistochemical staining proMBP localized only to the pla-
cental septa and the anchoring villi and proMBP mRNA was found only in the extravillous 
trophoblasts (Bonno et al., 1994). 
In cell culture conditions it was shown that human villous cytotrophoblasts produce active 
PAPP-A (Giudice et al., 2002). Moreover, PAPP-A protein and activity were found to be 
associated with the membranes of human trophoblasts (a mix of villous cytotrophoblasts 
and syncytiotrophoblasts) grown in cell culture (Sun et al., 2002) and in the cytoplasm of 
human villous cytotrophoblasts collected from placentae at different phases of pregnancy 
(Guibourdenche et al., 2003). In vitro differentiation of the villous cytotrophoblasts into 
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tein expression (Guibourdenche et al., 2003). Moreover, PAPP-A protein expression is 
significantly higher in cultured human invasive extravillous trophoblasts than in villous 
cytotrophoblasts (Fournier et al., 2008). Thus, the activity of PAPP-A seems to be impor-
tant in the feto-maternal interface.  
The group of Giudice (2002) showed that endometrial cells of the uterus produce signifi-
cantly lower levels of PAPP-A than villous cytotrophoblasts in cell culture. However, the 
production was significantly enhanced by the decidualization (i.e. maturation of the endo-
thelium to become a part of the placenta) achieved in vitro by treatment with estradiol and 
progesterone. This was already predicted by early studies in the 1980s with endometrium 
tissue samples and uterine fluid samples from women with hormonal treatment (reviewed 
by Rosen, 1986). Decidualization did not induce proMBP production in endometrial cells 
(Giudice et al., 2002). However, the treatment of decidualized endometrial cells with IGF-
II increased proMBP production but decreased PAPP-A production providing a possible 
regulatory feed-back loop for the IGF releasing activity of PAPP-A on the maternal side of 
the placenta.  
The role of PAPP-A in pregnancy is not yet well understood. As the only currently known 
activity of PAPP-A entails the release of IGFs from binding proteins, some conclusions can 
be drawn from this. Low maternal circulating IGF is associated with slower fetal growth 
and it has been suggested that this is due to defective placental development and function 
(Forbes and Westwood, 2008). In developing placenta a strictly regulated interaction be-
tween the differentiated fetal trophoblasts and the maternal decidua is crucial for normal 
placental development. The regulation assures “not too shallow but not too deep” invasion 
of fetal trophoblasts into the uterine wall. IGFs promote the differentiation of villous cyto-
trophoblasts into extravillous trophoblasts and the migration of these cells to the maternal 
decidualized endometrium. In the decidualized endometrium extravillous trophoblasts 
transform the uterine spiral arteries by widening them and thus enable and increase mater-
nal blood flow to the interstitial space of the placenta (Forbes and Westwood, 2008). IGFs 
also stimulate the differentiation of villous cytotrophoblasts into the multinucleated 
syncytiotrophoblast that lines the chorionic villi and acts as a nutrient and gas exchange 
membrane, a protective barrier and a source of pregnancy-specific hormones secreted to 
the maternal blood (Forbes and Westwood, 2008).  
PAPP-A expression in syncytiotrophoblasts and extravillous trophoblasts, among possible 
other yet unknown effects, presumably further promotes the differentiation of these cells 
and extravillous trophoblast invasion. In Down’s syndrome pregnancies a defect in 
syncytiotrophoblast differentiation has been noticed which leads to decrease in the synthe-
sis and secretion of pregnancy-specific hormones by the placenta (Massin et al., 2001). 
Moreover, defective trophoblast invasion is directly involved in pre-eclampsia, a major and 
frequent complication of human pregnancy (Fournier et al., 2008). In both conditions lower 
PAPP-A levels have been measured in the circulation during pregnancy (Wald et al., 1992; 
Spencer et al., 2008b). 
In 1979, Smith and colleagues showed that PAPP-A is predominantly secreted from the 
placenta to the placental compartment, not to the fetal compartment, as no PAPP-A was 
found in the cord artery, the cord vein or amniotic fluid. Significantly lower levels of 
PAPP-A were reported in peritoneal fluid than in peripheral blood implying that PAPP-A 
does not easily transfer from blood to interstitial fluid. Interestingly, PAPP-A concentra-
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tions were lower in retroplacental blood than in peripheral blood or in the uterine vein. This 
suggests that PAPP-A is not simply secreted by the chorionic villi directly into the intervil-
lous space of the placenta but possibly makes its way into the maternal circulation by a 
more circuitous route (Smith et al., 1979). 
As previously discussed, in late pregnancy plasma most PAPP-A (>99%) appears to be in 
complex with proMBP (Overgaard et al., 2000). PAPP-A complexation probably takes 
place in the placenta after PAPP-A and proMBP have been secreted by cells because 
PAPP-A seems to be produced mostly by different cells than proMBP in the placenta 
(Bonno et al., 1994) and active PAPP-A dimer binds to cell surfaces (Laursen et al., 
2002b), which promotes complex formation and detachment of the complex (Sivanandam 
et al., 2004). Moreover, no complex formation has been detected in serum samples col-
lected from women in the first trimester of pregnancy as PAPP-A activity in the samples 
remains stable (Gyrup et al., 2007). In addition, the half-life of active dimeric PAPP-A in 
the circulation is very short compared to the half-life of the complexed form (Glerup et al., 
2007).  
The complexation of the majority of PAPP-A prior to appearing in blood seems rational 
when considering the physiological role of PAPP-A. In this way PAPP-A is active in the 
placenta where it locally releases active IGFs from the binding proteins. When released to 
circulation, the complexation prevents excessive PAPP-A activity and IGF activation in the 
pregnant woman. However, recent evidence by Gyrup and colleagues (2007) showed that 
in early pregnancy the ratio of active PAPP-A over total PAPP-A detected in serum is 
higher: at gestational week 10 ~10% of PAPP-A is in active form. The activity of PAPP-A 
in pregnancy serum increased with gestational age but the relative amount of active PAPP-
A decreased. The meaning and implications of these findings remain to be elucidated. One 
possibility is that the pregnancy related changes in the pregnant women may also require 
increase of free IGFs in other parts of the body. 
Although PAPP-A seems important in human pregnancy, PAPP-A gene deficient mice are 
fertile (Conover et al., 2004a). However, significant inter-species differences seem to exist 
especially related to the role of PAPP-A in pregnancy between mouse and human. In strik-
ing contrast to human, in mice PAPP-A mRNA expression is not significantly higher in the 
placenta than in other tissues and the circulating concentrations of PAPP-A protein are not 
elevated during pregnancy in mice (Soe et al., 2002). 
2.3.2 Atherosclerotic plaques 
Atherosclerosis is a condition that affects the arteries of the human body. It involves forma-
tion of lesions to the innermost layer of the arteries, the tunica intima, which lies between 
the endothelium and the smooth muscle layer referred to as the tunica media (Fig. 5). The 
process of lesion formation and progression is complex and inflammation has been shown 
to play an important role in it. The mechanisms for lesion development initiation and pro-
gression are gradually becoming elucidated. Factors causing endothelial dysfunction and 
activation of inflammatory reactions in the cell wall seem essential including hypertension, 
smoking, high levels of low density lipoprotein (LDL) and hyperglycemia-associated prod-
ucts of glycoxidation in the circulation. Other factors involve proinflammatory cytokines 
derived from the excess adipose tissue and disturbed blood flow especially affecting the 
sites of curvature and branching of the arteries. (For reviews, see Lusis, 2000; Libby and 
Theroux, 2005; Hansson and Libby, 2006.) 
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Figure 5. An atherosclerotic plaque that has formed into the wall of an artery at the tunica intima layer 
between the endothelium and the smooth muscle layer, the tunica media. Typical characteristics include 
abundance of activated macrophages (mp) and macrophage derived lipid-filled foam cells (fc), a necrotic 
core with lipids and debris of dead cells, new blood vessels growing into the plaque from the tunica media 
and a thin cap that covers the plaque. (Adapted from original figure by S.Wittfooth in Eriksson et al., 
2006) 
The early forms of atherosclerotic lesions, known as fatty streaks, are characterised by 
accumulation of lipids and infiltration of inflammatory cells. These are already seen in 
young individuals. However, the fatty streaks do not cause symptoms and may either 
evolve further or regress. Mature lesions known as atherosclerotic plaques are character-
ized by lipid-filled macrophage-derived foam cells, extracellular lipids and debris of dead 
cells that form a necrotic core, capillary blood vessels that have grown into the plaque from 
the vasa vasorum (the arteries that supply the cells of blood vessels), high inflammatory 
cell infiltration (mainly activated macrophages and T cells most prominent in the shoulder 
area of the plaque) and a VSMC and collagen-rich endothelium-surfaced cap (covers the 
plaque and separates it from the lumen of the artery). (For reviews, see Lusis, 2000; Libby 
and Theroux, 2005; Hansson and Libby, 2006.) 
Clinical symptoms due to atherosclerotic plaques appear when the cap of a plaque ruptures 
inducing thrombus formation within the artery or when a plaque grows to a size that re-
stricts the blood flow through the artery rendering it insufficient. Thus, acute symptoms are 
usually caused by a certain plaque. However, as the reasons inducing lesion formation and 
progression can affect the whole vasculature, the lesions are not restricted to one site in an 
individual. Therefore, instead of a focal process, atherosclerosis should be seen as a sys-
temic disease. Accordingly, patients with symptoms of a certain atherosclerosis-related 
condition are usually at higher risk for atherosclerosis-related symptoms also in the other 
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PAPP-A in vascular tissue samples 
Bayes-Genis and colleagues (2001a) found PAPP-A in the atherosclerotic coronary plaques 
of patients who died of cardiac causes. The presence of PAPP-A was determined by stain-
ing of tissue samples with a PAPP-A specific monoclonal antibody. The staining was sig-
nificantly higher in the culprit (i. e. the plaque that was assumed to have caused the death) 
eroded or ruptured plaques than in stable plaques in the same individuals. In plaques with 
large lipid cores and cap rupture PAPP-A was found mostly in the inflammatory shoulder 
region and in the areas surrounding the lipid core. Staining was also localized to the mono-
cyte/macrophages. In fibrous plaques PAPP-A staining was detected with the spindle-
shaped smooth-muscle cells, in the extracellular matrix and in the noneroded endothelial 
cells.  
Sangiorgi and colleagues (2006) found PAPP-A in tissue samples of the plaques of the 
carotid artery. The plaque tissue was collected from patients who underwent carotid en-
darterectomy to remove those lesions. Immunohistochemical staining with a PAPP-A spe-
cific monoclonal antibody showed significantly higher staining in tissue samples of plaques 
with vulnerable or ruptured structure than in samples of stable plaques. A strong and dif-
fuse PAPP-A staining was evident mainly in the cap and the shoulder region of the plaque 
and colocalized strongly with the monocyte/macrophages. The intensity of PAPP-A stain-
ing correlated inversely with the cap thickness and positively with the intensity of inflam-
mation.  
In the immunohistochemical staining studies by Bayes-Genis and colleagues (2001b) the 
PAPP-A staining was shown to increase in porcine arteries after coronary overstretch bal-
loon injury. The presence of PAPP-A was most pronounced in the neointima and in the 
media 14-28 days after the injury; i.e. at the time of active cell migration, proliferation and 
protein synthesis. This implies that PAPP-A was locally produced rather than transported 
to the site by tissue infiltration from plasma as a response to the vascular injury. Similarly, 
in a study conducted by Smith and colleagues (2001), adult rat femoral artery tissue ex-
tracts showed significant increase in PAPP-A activity within 12-24 h after a balloon injury 
and the increased activity persisted for 6 days. Moreover, Resch and colleagues (2006b) 
showed that unilateral carotid artery ligation in mice lead to a marked elevation in PAPP-A 
mRNA expression that was associated with progressive increase in neointimal hyperplasia 
detected 7 to 14 days later. On day 28 after the ligation injury, in many cases wild-type 
mice had a complete occlusion of the carotid artery while PAPP-A KO mice showed 75% 
reduction in the neointimal area. Furthermore, the proliferation of cells in the neointimal 
areas of the injured vessels was greatly reduced in PAPP-A KO mice.  
Cells in atherosclerotic plaques 
VSMC, endothelial cells (EC) and macrophages are cells involved in the development of 
atherosclerotic plaques. IGFs have been shown to have proatherogenic effects on these 
cells (summarized in Figure 6) and are possibly released from IGFBPs in the atheroscle-
rotic lesions by PAPP-A. VSMC show high basal expression of PAPP-A (Bayes-Genis et 
al., 2001b; Conover et al., 2008a). In VSMC cell culture studies it has been noticed that the 
proinflammatory cytokines TNFα, IL-1β and IL-6 stimulate the expression of PAPP-A 
mRNA, protein and activity (Conover et al., 2006; Conover et al., 2008a). Increase in 
PAPP-A activity has also been shown in VSMC cultures which have been injured by scrap-
ing in vitro (Bayes-Genis et al., 2001b). IGFs released by PAPP-A induce changes in 
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VSMC cell cycle that lead to proliferation and migration of the cells – actions important in 
plaque formation after vascular injury (Bayes-Genis et al., 2000). However, VSMC from 
PAPP-A KO mice lack IGFBP-4 protease activity and fail to respond this way to treatment 
with IGF-I in the presence of IGFBP-4 (Resch et al., 2006b). 
 
Figure 6. The proatherogenic effects of IGFs on cells found in atherosclerotic plaques. PAPP-A may 
mediate these effects by releasing IGF from the binding proteins. 
Human coronary artery EC show little basal expression of PAPP-A (Conover et al., 2008a). 
However, the proinflammatory cytokines TNFα and IL-1β also stimulate PAPP-A expres-
sion in EC (Conover et al., 2008a). The IGF effects on EC, possibly mediated by PAPP-A 
degradation of the binding proteins, include promotion of migration and tube-formation. 
The tube-formation serves angiogenesis, i.e. growth of new blood vessels, which is impor-
tant in the development of plaques (Bayes-Genis et al., 2000). However, in addition to 
these potently proatherogenic effects, IGFs may also protect against endothelial dysfunc-
tion, an important cause of atherogenesis (Conti et al., 2004). 
Although otherwise expected from earlier immunohistochemical studies (Sangiorgi et al., 
2006), it was recently shown by Conover and colleagues (2007) that macrophages do not 
express PAPP-A protein or mRNA. No PAPP-A expression was detected in human periph-
eral blood monocytes and cells of acute monocyteic leukaemia cell line THP-1 which were 
differentiated into macrophages and further activated in vitro. The case was similar with 
activated macrophages isolated from a hypecholesterolemic rabbit model of atherosclero-
sis. However, as previously mentioned, macrophages were found to bind and internalize 
PAPP-A. Moreover, activated macrophages were much more efficient in this than unacti-
vated macrophages or monocytes (Conover et al., 2007). In macrophages IGFs promote 
chemotaxis, excess LDL uptake and release of proinflammatory cytokines such as TNFα. 
These effects are possibly mediated by PAPP-A through the release of active IGFs from the 
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produce PAPP-A themselves, they produce cytokines that stimulate PAPP-A production in 
the surrounding EC and VSMC. This may lead to a positive feed-back loop, as the PAPP-A 
produced by EC and VSMC and bound by macrophages may increase the amount of active 
free IGFs that stimulates the cytokine production in the macrophages.  
PAPP-A deficient mice 
ApoE KO mice serve as a model of atherosclerosis because when fed with a high-fat diet, 
the ApoE KO mouse has 10-fold higher total serum cholesterol levels than wild-type mice 
and produce aortic lesions that are similar to atherosclerotic lesions found in humans. Har-
rington and colleagues (2007) noticed that in ApoE KO mice PAPP-A mRNA was ex-
pressed at 20-fold higher levels in lesional areas compared to other areas of the aorta. In 
double ApoE PAPP-A KO/KO mice total serum cholesterol increased similarly as in ApoE 
KO mice but the lesion area was reduced 70-80% after 10 weeks on high-fat diet. How-
ever, there was no significant difference in the lesion number. Thus, PAPP-A seems to 
have a predominant effect on lesion progression rather than on the lesion initiation. The 
lesions of ApoE KO mice were more complex with significantly greater necrotic core ar-
eas, while the extent of inflammation determined as macrophage staining or IL-1β or TNFα 
expression did not differ between ApoE KO and double ApoE PAPP-A KO/KO mice 
(Harrington et al., 2007).  
Effects of cardioprotective resveratrol 
Recently, Conover and colleagues (2006) showed that pretreatment with resveratrol, a 
polyphenol found in the skin of grapes and in red wine, inhibited the TNFα and IL-1β-
induced PAPP-A mRNA and PAPP-A activity expression in VSMC. However, resveratrol 
did not affect basal PAPP-A mRNA expression or activity. The induced inhibition of 
IGFBP degrading activity was not due to induction of proMBP. It was suggested that the 
cardioprotective effects of resveratrol may, in part, be a result of the blocking of cytokine-
stimulated PAPP-A expression. 
2.3.3 Folliculogenesis 
Folliculogenesis represents the process in which oocytes mature in the female ovaries to 
become ready for ovulation and fertilisation (Fig. 7). The process proceeds from the pri-
mordial follicles, through the stages of preantral, antral and preovulatory follicles, to the 
graafian follicle that releases the oocyte in ovulation. The process is controlled by the folli-
cle stimulating hormone (FSH) produced by the pituitary gland. Although many follicles 
start their maturation within a certain menstrual cycle, the growth of the majority of the 
follicles ceases at some stage of the process. These follicles become atretic and degenerate. 
Due to signals not yet well understood only one follicle is chosen to become the dominant 
follicle and to ovulate in the monovulatory species. After ovulation, the remaining follicle 
tissue degenerates to form a corpus luteum. (Reviewed by Zeleznik, 2004.) 
The disappearance of IGFBP-2, -4 and -5 in the fluid of preovulatory follicles and the in-
crease in their levels in atretic follicles is a conserved phenomenon among mammalian 
species (Mazerbourg et al., 2003). Protease-induced decreases in IGFBP-2, -4 and -5 and, 
in the case of IGFBP-2, reduced expression, most likely cause increased levels of bioavail-
able IGFs. This seems to stimulate steroidogenesis and mitogenesis in the developing 
dominant follicles, which ultimately prepare the follicles and oocytes for successful ovula-
tion and fertilization (Monget et al., 2003; Gerard et al., 2004; Spicer, 2004). In atretic 
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follicles IGFBPs sequester the available IGF and degeneration of the follicle takes place 
(Monget et al., 2003). 
Figure 7. The stages of folliculogenesis. A) A primordial follicle with one granulosa cell layer and the 
oocyte. B) A preantral follicle with several layers of granulosa cells and theca cells forming the theca that 
surrounds the basal membrane around the granulosa cells. C) An antral / a preovulatory follicle with an 
antrum, cumulus granulosa cells (cgc) around the oocyte, membrane granulosa cells (mgc) next to the 
basal membrane and theca around the basal membrane. 
PAPP-A has been identified as the IGFBP-2, -4 and -5 protease in the follicular fluid of 
preovulatory follicles of various mammalian species (Chandrasekher et al., 1995; Rivera et 
al., 2001; Gerard et al., 2004). Importantly, this activity has been found to be significantly 
higher in the estrogen producing follicles destined to proceed further than in the subordi-
nate follicles destined for atresia (Chandrasekher et al., 1995; Rivera et al., 2001; Rivera 
and Fortune, 2001; Matsui et al., 2004). Moreover, higher activity of PAPP-A in the fol-
licular fluid of competing antral follicles even before apparent size divergence or increased 
estrogen production predicts dominance (Rivera and Fortune, 2003a). Thus, PAPP-A 
seems to have an important role in the selection of the dominant follicle due to ovulate. 
Hourwitz and colleagues (2000) found the expression of PAPP-A mRNA to follow a simi-
lar pattern as the detected activity. PAPP-A mRNA expression was detected in the healthy 
human ovaries of normal cycling women exclusively in the granulosa cells of healthy an-
tral follicles from a diameter of 5 mm to the preovulatory stage. Expression was also seen 
in a subset of large luteal cells assumed to be granulosa lutein cells in healthy corpora 
lutea. On the other hand, PAPP-A mRNA expression is low or undetectable in preantral 
follicles, in atretic antral follicles and in connective tissue cells.  
In developing follicles, PAPP-A expression seems to be induced by FSH. FSH injection 
just before the time of dominant follicle selection in heifers and in cows led to formation of 
codominant follicles with IGFBP-4 degrading activity similar to dominant follicles of un-
treated animals (Rivera and Fortune, 2001; Rivera and Fortune, 2003a). Accordingly, in rat 
follicle membrane granulosa cells PAPP-A mRNA expression was markedly stimulated by 
FSH (Matsui et al., 2004) and FSH increased the IGF-dependent IGFBP-4 degradation in 
cell cultures of luteinizing human granulosa cells (Iwashita et al., 1998).  
Spatial specific control mechanisms over PAPP-A activity seem to exist in the developing 
follicle which arise from variable expression regulation. The stimulation of PAPP-A 
mRNA expression in rat follicle membrane granulosa cells by FSH is inhibited by bone 
morphogenetic protein (BMP)-15. BMP-15 is produced by the oocytes and this results in 
lower PAPP-A activity near the oocyte (Matsui et al., 2004). Moreover, although the ex-
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pression of PAPP-A by the granulosa cells of the small and large follicles of bovine ovaries 
is not affected by estradiol, in theca cells estradiol decreases PAPP-A mRNA levels (Aad 
et al., 2006). Pregnant mare serum gonadotropin stimulates PAPP-A expression in mouse 
membrane granulosa cells of healthy antral / dominant follicles and in the granulosa-lutein 
cells of corpus luteum; however, this effect was not seen with cumulus granulosa cells 
(Hourvitz et al., 2002). Similarly, pregnant mare serum gonadotropin induces PAPP-A 
expression in the membrane granulosa cells of healthy dominant follicles of rat ovary but 
not in cumulus granulosa cells juxtaposed to the oocyte or any granulosa cells of atretic 
follicles (Matsui et al., 2004).  
A small number of studies have focused on PAPP-A in relation to in vitro fertilization. It 
has been shown that the ovulation hyperstimulating agent (either gonadotropin releasing 
hormone agonist or antagonist) does not affect the PAPP-A levels of the follicular fluid. 
However, the PAPP-A concentration on the day of oocyte retrieval is inversely related to 
the growth and survival of the oocyte (Choi et al., 2006). In another study, low concentra-
tion of PAPP-A in follicular fluid on the day of oocyte retrieval predicted better oocyte 
maturation and early embryo development (Wang et al., 2006). Thus, in spite of the pro-
moting role in the selection and growth of dominant follicle, the activity of PAPP-A may 
only play a minor role, if any, in final oocyte maturation and subsequent embryo develop-
ment.  
The issue of PAPP-A inhibition by proMBP in relation to folliculogenesis has been little 
studied. In immunohistochemical studies, Rhoton-Vlasak and collegues (2003) detected 
PAPP-A and proMBP expression with distinct patterns in human ovarian tissue during 
folliculogenesis. However, in luteal tissue the localization patterns of PAPP-A and 
proMBP were similar. In the study by Kalli and colleagues (2004) ovarian surface epithe-
lial cells were found to express high levels of PAPP-A mRNA, protein and activity but no 
proMBP mRNA or protein. The results imply that PAPP-A is most likely not inhibited by 
proMBP around the cells where activity is required during folliculogenesis, while in luteal 
tissue inhibition may take place and be important to avoid the adverse effects of excessive 
PAPP-A activity. 
2.3.4 Osteogenesis 
PAPP-A mRNA and protein are expressed by human osteoblasts and osteoprogenitor cells, 
the cells important in the formation of bone tissue, i.e. osteogenesis (Lawrence et al., 
1999). PAPP-A seems to act as a potent anabolic factor in the regulation of bone formation 
because recombinant PAPP-A significantly increases the proliferation of osteoblasts and 
free IGF-1 concentration in the culture medium of human ostosarcoma cell line MG63 (Qin 
et al., 2006b). 
PAPP-A mRNA expression, PAPP-A protein secretion and IGFBP-4 degrading activity in 
the primary cultures of human osteoblastic cells are stimulated by BMP-2 and proinflam-
matory cytokines transforming growth factor-β, TNFα, IL-1β and IL-4 (Ortiz et al., 2003; 
Conover et al., 2004b; Jadlowiec et al., 2005). BMP-2 and PAPP-A are probably involved 
in the mediation of end-stage osteoblastic differentiation as they can together stimulate 
matrix mineralization by human adult mesenchymal cells in the absence of other osteo-
genic supplements (Jadlowiec et al., 2005). PAPP-A also seems to promote bone angio-
genesis as noticed in the chick chorioallogenic membrane model (Jadlowiec et al., 2005). 
Thus, cytokine-regulated PAPP-A may play a role in normal bone remodelling, fracture 
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repair and in abnormal bone remodelling associated with inflammation (Conover et al., 
2004b). 
In PAPP-A KO mice the development of bones is delayed during embryogenesis (Conover 
et al., 2004a). Adult PAPP-A KO mice show skeletal insufficiency of mass, density, archi-
tecture and strength (Tanner et al., 2008). The bones are smaller and weaker because more 
bone is destroyed than formed (Tanner et al., 2008). Moreover, fracture healing is signifi-
cantly delayed, although eventually the fractures also heal in PAPP-A KO mice (Miller et 
al., 2007). Thus, PAPP-A KO mice may represent a model of age-related osteoporosis with 
increased fracture risk. 
PAPP-A has also been found by Gruber and colleagues (2008) in human intervertebral 
discs where it seems to be expressed in inner anulus cells especially when the discs are 
degenerating. The role of PAPP-A has been suggested to be linked to the repair of the de-
gerated disc tissue by releasing active IGF. IGFs have been reported to prevent or retard 
apoptosis of cultured human anulus cells and to stimulate proteoglycan synthesis within the 
disc. 
2.3.5 Myogenesis 
PAPP-A may be important in myogenesis, in the developmental program that generates 
and regenerates skeletal muscle. Rehage and colleagues (2007) showed that in normal 
wild-type mice with induced muscle injury the expression of PAPP-A was shown to be 
significantly increased five days after injury, while the expression was normal on day 14. 
In a study by Kumar and colleagues (2005) exogenous recombinant PAPP-A and transient 
overexpression of PAPP-A in a mouse myoblast cell line C2C12 increased the proliferation 
in a dose- and time-dependent manner. PAPP-A also enhanced myotube formation and the 
activity of creatine kinase implying that PAPP-A promotes myoblast differentiation. As 
IGFs potently stimulate the proliferation and differentiation of myogenic cells, the stimula-
tory effect seems to depend on the ability of PAPP-A to increase the amount of free IGF-I 
through IGFBP degradation  
In vivo studies with genetically modified mice by Rehage and colleagues (2007) have also 
provided evidence that PAPP-A is a promoter of skeletal muscle formation and growth. 
Targeted overexpression of PAPP-A in the muscles of mice was achieved with the use of 
muscle-specific promoter (human skeletal α-actin promoter). The prenatal and the postnatal 
growth were significantly enhanced in the genetically modified mice. At the age of 10 
weeks the genetically altered mice were 20-50% heavier and 9% longer than wild-type 
mice at that age. The skeletal muscle weight and muscle fiber area were also increased. 
Moreover, free IGF-I concentration was remarkably increased in the culture medium of ex 
vivo cultured muscle cells from transgenic mice and the proliferation of C2C12 myoblasts 
significantly increased in the presence of this culture medium.  
2.3.6 Skin wound healing 
With PAPP-A specific immunohistochemical staining, PAPP-A has was found by Chen 
and colleagues (Chen et al., 2003) in human skin at the epidermis, in sweat and sebaceous 
gland epithelial cells, in hair follicles and in endothelial cells of the blood vessels. Injury 
led to an increase in the localization of PAPP-A in the dermal granulation tissue within and 
adjacent to the injury, in small blood vessels, on newly synthesized collagen and at the 
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advancing epithelial edge of the healing epidermis. The PAPP-A staining colocalized with 
activated wound fibroblasts showing spindle-shaped morphology and with activated wound 
macrophages but not with lymphocytes. In the healing skin, PAPP-A is presumably in-
volved in the tissue healing process by releasing IGF that acts as a stimulant of keratino-
cyte and fibroblast proliferation and matrix protein synthesis.  
2.3.7 Cancer 
As a mediator of IGF availability, PAPP-A is a potent cell growth promoter and accord-
ingly some studies have shown that PAPP-A activity is important in malignancy. In a study 
by Suzuki and colleagues (2003) glycoprotein bikunin suppressed cancer cell invasion and 
metastasis and transiently suppressed the expression of PAPP-A in human ovarian cancer 
cell line HRA. Treatment of the cells with 18-base phosphorothioate antisense PAPP-A 
oligodeoxynucleotide had a similar effect. Moreover, Tanaka and colleagues (2004) 
showed that, after intraperitoneal tumor cell inoculation into mice, PAPP-A mRNA and 
protein became markedly upregulated in intraperitoneal disseminated metastatic tumors. In 
contrast, antisense PAPP-A significantly suppressed the growth of these cells. Genetic 
deletion of PAPP-A in mice has been shown to lead to 30-40% increase in life-span and a 
sharp reduction in the incidence of spontaneous tumors (Conover and Bale, 2007; Conover 
et al., 2008b). In the study by Conover and Bale (2007), at the age of 23- to 28- months 
~70% of the wild-type mice had developed tumors affecting primarily liver, lung, kidney 
and colon while only 15% of the PAPP-A KO mice had small tumors that were located in 
the liver.  
In some cases, however, PAPP-A has been shown to be negatively associated with malig-
nancy. PAPP-A mRNA and protein are expressed by human osteoblasts and osteoprogeni-
tor cells but not by osteosarcoma cells (Lawrence et al., 1999). PAPP-A expression is also 
lower in ovarian tumours than in normal ovarian cells (Alexiadis et al., 2006). Moreover, 
while dibutyryl cyclic adenosine monophosphate (dB-cAMP) reverses the transformed 
malignant phenotype of human glioblastoma cells U87MG, it also increases the expression 
PAPP-A among other genes (Moreno et al., 2006). Induction of PAPP-A mRNA expres-
sion by another cAMP derivative, 8-bromo-cAMP, has also been reported in a choriocarci-
noma cell line JAR (Haaning et al., 1996).  
Apparently, some tumor promoters seem to induce production of proMBP, the specific 
inhibitor of PAPP-A. Chen and colleagues (2002) showed that in cultured human fibro-
blasts a phorbol ester tumor promoter β-phorbol 12,13-didecanoate (β-PDD) induced inhi-
bition of the activity of PAPP-A against IGFBP-4 by stimulating proMBP expression. 
Transformation with simian virus large T antigen or treatment with another phorbol ester 
tumor promoter PMA also had a similar effect.  
Inhibition of PAPP-A activity in malignancy has also been shown in a study by Kalli and 
colleagues (2004). Ovarian tumor cells were found to express variable levels of PAPP-A 
but relatively high amounts of proMBP protein and mRNA and, probably as a result, negli-
gible PAPP-A activity. Similarly, in a reversible premalignant ovarian surface epithelial 
cell model system, the premalignant cells proliferated but produced low amounts of PAPP-
A mRNA, protein and activity. When the premalignant state was reversed, proliferation 
ceased and PAPP-A mRNA and protein expression and PAPP-A activity increased signifi-
cantly. Thus, there seems to be an association between the normal phenotype of ovarian 
cells and PAPP-A activity.  
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2.4 PAPP-A as a circulating biomarker 
In this section are reviewed studies related to the use of PAPP-A as a circulating biomarker 
in various conditions. However, it should be noted that currently PAPP-A has been adopted 
into clinical use only for prenatal screening of Down’s syndrome during the first trimester 
of pregnancy. For this purpose PAPP-A is widely used in the developed countries world-
wide. 
2.4.1 Pregnancy 
The circulating levels of PAPP-A have been found to increase throughout pregnancy until 
delivery (Smith et al., 1979; Folkersen et al., 1981; Rosen, 1986). Elevated levels are de-
tected already at the 4th gestational week (median 11 µg/L, 31 mIU/L) (Qin et al., 1996) 
and the concentrations seem to reach at least 30 000 µg/L (~100 000 mIU/L) by the time of 
delivery, although variation in the determined concentrations is high between individuals 
and the detection methods used (Folkersen et al., 1981; Rosen, 1986; Oxvig et al., 1995). 
After delivery, the PAPP-A levels normalize with an average half-life of 51 h within 5 
weeks (Smith et al., 1979).  
Down’s syndrome 
In the early 1990s it was realised that lower levels of serum PAPP-A were associated with 
Down’s syndrome (DS) pregnancies (Wald et al., 1992). In this first study by Wald and 
colleagues serum PAPP-A was compared between DS cases and controls matched with 
gestational age as multiples of the median (MoM) of the control group and this has re-
mained the practice since. In samples collected in the first trimester of pregnancy, between 
gestational weeks 9 and 12, the median MoM of 19 DS cases was 0.23. Subsequently, it 
was soon noticed that PAPP-A was not a good marker in the second trimester but showed 
better discrimination in the first trimester (Cuckle et al., 1992). By the end of the first dec-
ade of the 21st century PAPP-A has been widely implemented into the Down’s syndrome 
screening regimes in developed countries. Although the discriminating power of PAPP-A 
alone is not high (52% of DS cases detected with a false positive rate of 5%), it is of sig-
nificant benefit in multimarker approaches (Cuckle and van Lith, 1999).  
Previously, second trimester screening (15-18 weeks of gestation) including maternal age 
and maternal serum concentrations of α-fetoprotein, unconjugated estriol and human chori-
onic gonadotropin (hCG) was the mainstay of prenatal DS screening (Benn, 2002). How-
ever, currently the best prediction of the incidence of DS pregnancy is obtained with first 
trimester screening (10-14 weeks of gestation) protocol that combines serum PAPP-A with 
maternal age (DS risk increases with age), the diameter of the fetal non-echogenic nuchal 
edema commonly referred to as nuchal translucency (DS risk increases with larger diame-
ter) and serum free β-form of hCG (DS risk increases with elevated concentration). With 
this procedure a detection rate of ~90% for DS has been achieved with a false-positive rate 
of 5% in retrospective and prospective studies (Spencer et al., 1999; Bindra et al., 2002; 
Spencer et al., 2003; Nicolaides et al., 2005; Canick et al., 2006). Such non-invasive 
screening procedures help in choosing the women in high DS pregnancy risk for invasive 
confirming examination with amniocentesis or chorionic villi biopsy. In addition to offer-
ing better risk prediction with lower false-positive rate compared to second trimester 
screening, the first trimester screening provides earlier reassurance for those with a normal 
result and possibly less traumatic pregnancy termination for those receiving abnormal re-
sults also from the confirming test. 
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Certain factors may affect PAPP-A concentrations during pregnancy and thus confound the 
risk calculations. For example, the number of fetuses should be taken into account as well 
as the chorionicity because PAPP-A levels are generally higher in twin pregnancies but in 
monochorionic twin pregnancies PAPP-A levels are lower than in dichorionic twin preg-
nancies (Spencer et al., 2008c). The ethnic origin of the pregnant woman also has an influ-
ence as, for instance, the circulating concentrations in the first trimester are significantly 
higher in Afro-Caribbean than in Caucasian women, which possibly leads to underestima-
tion of DS risk in pregnant women of Afro-Caribbean origin (Kagan et al., 2008). On the 
other hand, smoking and the use of assisted reproductive technologies decrease PAPP-A 
levels thus increasing the rate of false-positive screening results (Kagan et al., 2008; Amor 
et al., 2009). 
Other pregnancy abnormalities 
In addition to DS caused by the trisomy of the 21st  chromosome, lower PAPP-A values are 
also associated with other genetic anomalies and birth defects. Lower levels of maternal 
serum PAPP-A have been seen in pregnancies affected by the trisomy of chromosomes 13 
and 18 as well as by maternal and paternal triploidy. It has been shown that maternal serum 
PAPP-A can be used together with maternal serum βhCG and nuchal translucency thick-
ness to identify such cases (Spencer et al., 2000; Spencer, 2007). Low maternal circulating 
PAPP-A levels are also associated with Cornelia de Lange syndrome, a rare congenital 
defect with typical physical characteristics (Westergaard et al., 1983a; Chong et al., 2009). 
Interestingly, PAPP-A protein was not detected in the plancentae of pregnancies compli-
cated by Cornelia de Lange syndrome in striking contrast to normal pregnancy with abun-
dant PAPP-A in syncytiotrophoblast tissue (Westergaard et al., 1983a). Chong and col-
leagues (2009) recently reported that Cornelia de Lange syndrome may be detected by low 
maternal serum PAPP-A and following detailed ultrasound examination in first trimester 
screening.  
Montanari and colleagues (2009) noticed that in fetuses with normal karyotype low first 
trimester serum PAPP-A concentrations are also associated with reduced fetal size and 
higher risk of intrauterine fetal growth restriction with Doppler signs of impaired placental 
perfusion. However, only 10-16% of women with low PAPP-A values in the first trimester 
have a pregnancy complicated with fetal growth restriction (Montanari et al., 2009). In the 
study by Spencer and colleagues (2008b) low maternal circulating PAPP-A levels in the 
first trimester (11 to 13 weeks of gestation) were associated with developing pre-eclampsia 
and the risk for pre-eclampsia increased with decreasing PAPP-A concentrations. At a 
PAPP-A MoM of 0.415, 15% of the cases with pre-eclampsia were identified. 
Among pregnancies without chromosomal abnormalities Spencer and colleagues (2008a) 
reported an adjusted risk ratio of 2.1 [95% confidence interval (95% CI) 1.3-3.6] for the 
overall power of low PAPP-A levels (<0.4 MoM) to predict fetal loss, pre-eclampsia, se-
vere pregnancy-induced hypertension and small for gestational age infant. Thus, women 
with low PAPP-A early in pregnancy have twice the risk of an adverse outcome. Gesta-
tional age of 10-14 weeks was shown to be the only time period when low PAPP-A is sig-
nificantly associated with these adverse outcomes. The confounding factors affecting the 
ability of PAPP-A to predict risk included maternal weight, smoking and caffeine intake. 
Although the predictive power of PAPP-A for these adverse outcomes is low, it has been 
suggested that women with low first-trimester PAPP-A MoM and a fetus with normal 
karyotype should be monitored carefully to further assess the risk of pre-eclampsia and 
Review of the Literature 
 40 
poor fetal growth (Spencer et al., 2008b; Montanari et al., 2009). Extremely high PAPP-A 
levels sometimes encountered in the first trimester screening do not seem to be associated 
with adverse pregnancy outcome and they may possibly arise, at least in some cases, from 
detection method related bias (Cuckle et al., 2003). 
2.4.2 Acute coronary syndromes 
Acute coronary syndromes (ACS) are characterized by symptoms, most commonly severe 
chest pain, caused by a sudden obstruction of blood flow through a coronary artery that 
supplies oxygen to the heart muscle tissue. Most often the reason is thrombus formation 
within the coronary artery that was initiated by a rupture or superficial erosion of a coro-
nary atherosclerotic plaque. ACS are further classified as myocardial infarction (MI, a total 
block of the blood flow that results in necrosis of myocardial tissue) and unstable angina 
(UA, only partial or quickly resolving obstruction of blood flow that does not lead to de-
tectable myocardial necrosis). Moreover, MI can further be classified as MI with elevation 
of the ST-segment in ECG (STEMI) indicating severe dysfunction of the heart muscle and 
MI without elevation of the ST-segment in ECG (NSTEMI). NSTEMI and UA are both 
forms of ACS without ST-segment elevation and can therefore together be referred to as 
NSTE-ACS. (Reviewed by Morrow et al., 2007.) Pronounced atherosclerosis of the coro-
nary arteries, i.e. coronary artery disease (CAD), can also present as stable angina (SA). In 
SA the coronary plaques are large enough in size to obstruct blood flow and cause symp-
toms when the oxygen demand is increased, for example with physical stress. The symp-
toms are alleviated with rest and medication that reduces the oxygen demand or dilates the 
blood vessels. (Reviewed by Libby and Theroux, 2005.) It is noteworthy that SA is not 
considered as an ACS because the symptoms can be predicted. The classification of the 
forms of symptomatic presentation of CAD is summarized in Figure 8.  
Figure 8. Classification of the forms of coronary artery disease with symptoms. 
MI
Symptomatic conditions associated with






















Review of the Literature 
 41 
Elevation in the circulation of ACS patients 
In 2001, in the same study by Bayes-Genis and colleagues (2001a) in which they revealed 
that PAPP-A is exclusively found in eroded and ruptured atherosclerotic plaques, it was 
noted for the first time that the circulating levels of PAPP-A were elevated in ACS patients. 
PAPP-A concentrations were significantly higher in blood samples from patients diagnosed 
with MI or UA than in samples from SA patients or control subjects with normal coronary 
arteries. The PAPP-A levels were not associated with age, gender, traditional risk factors, 
medication, markers of cardiac necrosis including cardiac troponin I (cTnI) and MB iso-
form of creatine kinase (CK-MB) while association was noticed with the inflammation 
marker C-reactive protein (CRP) (r=0.61, p=0.02). At a cut-off level of 10 mIU/L, PAPP-A 
detected ACS cases with a sensitivity of 89.2% and a specificity of 81.3%. The details of 
the studies related to PAPP-A and ACS are summarized in Table 3. 
PAPP-A elevation in ACS has subsequently been confirmed by others. Khosravi and col-
leagues (2002) reported on higher PAPP-A concentrations in patients with positive cTnT 
and CK-MB than in CK-MB negative cardiac patients or apparently healthy controls. 
However, there was not a significant correlation between PAPP-A and cTnT or CK-MB 
concentrations. Laterza and colleagues (2004) also showed higher serum concentrations of 
PAPP-A in MI patients than in non-MI patients among patients admitted to hospital with 
ACS symptoms. The correlation between PAPP-A and cTnT was also poor in this study.  
In a study by Rossen and colleagues (2007) circulating PAPP-A levels were lower in 
NSTEMI patients than in STEMI patients and yet lower levels were seen in healthy con-
trols. Miedema and colleagues (2008) reported on higher circulating PAPP-A levels in 
ACS patients than in patients with stable angina or in asymptomatic CAD patients while 
Liu and colleagues (2008) noticed higher serum PAPP-A in STEMI and UA patients than 
in SA patients and controls. Iversen and colleagues (Iversen et al., 2008b) have also re-
ported on elevated circulating PAPP-A in STEMI patients.  
In a recent study by Schoos and colleagues (2009) higher PAPP-A levels were found in 
STEMI patients compared to high risk NSTE-ACS patients or to low-risk NSTE-ACS 
patients with even lower levels, although samples were available for most of the patients 
only 12 h after admission. Similarly, a recent study by Iversen and colleagues (2009) 
showed higher PAPP-A levels in high-risk NSTE-ACS patients than in low-risk NSTE-
ACS patients. Moreover, the PAPP-A concentrations of this whole patient group were 
lower than in STEMI patients but higher than in patients with non-cardiac disease or in 
healthy controls whose PAPP-A concentrations had been measured with the same method 
by the same group previously. 
Dominguez-Rodriguez and colleagues (2005) did not find significant difference in the se-
rum concentration of PAPP-A between MI patients and controls. However, in this study the 
control subjects were also admitted to hospital implying that these individuals were not 
healthy. Moreover, the ability of the assay used by this group to reliably detect the low 
concentrations reported has been questioned (Wittfooth et al., 2006). 
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Table 3. Summary of the clinical studies of PAPP-A in ACS patients. 
Study Patientsa Sampling                                    
timea 




Bayes-Genis                         
et al. (2001a) 
17 MI,                                       
20 UA,                                                      
19 SA,                                                        
13 controls 




MI 20.6 [9.2,46.6] mIU/L,                          
UA 14.9 [6.3,63.4] mIU/L,                                             
SA 8.4 [4.4,22.5] mIU/L,                        
controls 7.4 [3.8,10.4] mIU/L 
Possible 
Brügger-
Andersen                        
et al. (2007) 
20 STEMI with PCI,             
18 STEMI with TL 
Right before 
treatment,                        
immediately after 
PCI,                     
90 min after TL 
DSL Before PCI 0.62 [0.3,8.12] mIU/L,                                   
after PCI 4.26 [2.24,9.20] mIU/L, 
before TL 1.03 [0.31,14.71]mIU/L, 




Andersen                                             
et al. (2008) 
298 MI 4-6 days after 
admission 
DSL PAPP-A 0.5 [0.3,0.7] mIU/L Possible 
Dominguez-
Rodriguez                      
et al. (2005) 




DRG MI 1.29 (SEM 0.02) mIU/L,                            
controls 1.24 (SEM 0.07) mIU/L 
Not likely 
Elesber                                        
et al. (2007) 
59 intermediate to 
high risk ACP =>                       
final diagnosis:                                
19 ACS, 40 NCCP 
Admission   DSL ACS 2.0 [1.2,4.9] mIU/L,                                         
NCCP 1.2 [0.7,1.6] mIU/L 
Not likely
Furenes                    
et al. (2009) 
20 STEMI,                                                                    
10 SA 
SA before PCI, all 
3 and 12 h; 1, 3, 5, 
7 and 14 days after 
PCI 
DRG SA before PCI 5.90 ng/mL,                               
SA 3 h 9.48 ng/mL,                                                     
STEMI 3 h 7.62 ng/mL 
Possible 
Hájek                                                  
et al. (2008) 
66 STEMI,            
35 NSTEMI,                         
21 UA,                                   
110 SA,                                                   
51 controls  
During angiogra-





STEMI 17.75 [0,146.8] mIU/L,             
NSTEMI 14.3 [0,123.0] mIU/L                                
UA 11.4 [0,68.3] mIU/L,                                         
SA 8.1 [0,16.4] mIU/L,                                                 
controls 7.5 [0,14.2] mIU/L 
Possible 
Heeschen                                       




First available              
(8.7±4.9 h after 
symptom onset) 
Roche  9.3 [0.2,105.4] mIU/L Highly 
likely 
  644 ACP =>                                       
final diagnosis:                        
323 NSTE-ACS,            
105 SA, 19 CHF,                     




Roche ACS 4.9 [0.1,362.5] mIU/L,                               
SA 1.9 [0.1,113.9] mIU/L,                                         
no CHD 1.4 [0.1,54.1] mIU/L 
Not likely
Iversen                                                        
et al. (2008b) 
354 STEMI with PCI At admission 0.8 
[0,113.7] h after 
PCI, every 6-8 h 
until necrosis 
markers decreasing 
Rossen Admission 12.1 [2.0,224.2] mIU/L,         
2nd sample 2.2 [2.0,31.5] mIU/L,                      
3rd sample 2.0 [2.0,20.2] mIU/L 
Possible 
Iversen                                  
et al. (2009) 
123 high-risk                            
NSTE-ACS,                             
415 low-risk                     
NSTE-ACS 
At admission, 
every 6-8 h until 
necrosis markers 
decreasing 
Rossen 63% high-risk NSTE-ACS >4 
mIU/L,  49% low-risk NSTE-ACS 
>4 mIU/L 
Possible 
Kavsak                                             
et al. (2009) 
320 ACP Earliest possible 
for PAPP-A, 
repeated  samples 
for cTnI 
DSL Peak PAPP-A in heparin treated 
patients 4.03 [1.95,9.84] mIU/L,                                          
in patients without heparin treat-
ment 1.56 [1.79,1.97] mIU/L;                                
non-heparin cTnI negative patients: 
changing hs cTnI 1.88 [1.06,3.66] 




Khosravi                                      
et al. (2002) 
71 cardiac patients            
(3 serial sampling),                                                 
47 controls 
Unspecified DSL cTnT positive patients                                    
3.89 {0.01-97.0} mIU/L,                                                          
CK-MB positive patients                            
4.47 {0.31-16.5} mIU/L,                                                                            
CK-MB negative patients                                
1.07 {BDL - 4.99} mIU/L 
Possible 
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(continued from previous page) 
Study Patientsa Sampling                                    
timea 




Laterza                                                
et al. (2004) 




DSL MI 2.14 (SEM 0.39) mIU/L,                                              
non-MI 0.77 (SEM 0.08) mIU/L 
Possible
Liu                                        
et al. (2008) 
12 STEMI,                                                                     
15 UA,                                          
15 SA,                                     
16 controls;                                                     
24 of STEMI and 
UA treated with PCI 
ACS 30 min 
before PCI,                                      
SA 4 h before 




STEMI 16.9±10.3 mIU/L,                                
UA 15.2±10.5 mIU/L,                                           
SA 8.5±3.1 mIU/L,                               
controls 8.4±2.0 mIU/L,                  
before PCI 15.1±10.0 mIU/L,                                  
after PCI 19.9±10.1 mIU/L 
Possible
Lund                                                           
et al. (2003) 
136 cTnI negative 
ACS  
Admission, 6-12 
h, 24 h 
Qin Admission 2.3 [1.6,3.0] mIU/L;                                              
peak concentration mIU/L                                                      
in discharged 2.35 [1.6,2.9]             
in hospitalized 3.3 [2.1,6.5]  
Possible
Lund                                       
et al. (2006) 




12, 24 and 48 h 
(+1, 2, 4 h) 
Qin Frequent sampling patients:                             
admission 8.0 [3.7,12.2] mIU/L,                       
1 h 11.6 [4.7,18.8] mIU/L,                               
12 h 4.7 [3.0,6.3] mIU/L 
Possible 
McCann                                                                      
et al. (2008) 
415 ACP =>
final diagnosis:                                           
73 STEMI, 125 






Demeditec MI 6.7 [2.6,12.4] ng/mL,                                                         
non-MI 5.0 [1.7,11.0] ng/mL 
Not likely
McCann                                             
et al. (2009) 




Demeditec Death or MI in 1 year                                         
6.7 [3.0,13.4] ng/mL,                                
no adverse event                                            
6.3 [2.2-12.4] ng/mL 
Not likely
Qin                                      
et al. (2002b) 
14 MI,                                                 
1 UA 
Admission, 1, 2, 
4, 6, 24, 48, 72 h 
Qin Highly variable levels                                                               
between ~1-30 mIU/L 
Possible 
Rossen                          
et al. (2007) 
14 STEMI with 
PCI,                                                          





10 h from 
symptom onset 
Rossen STEMI 4.5-49.8 mIU/L,                                                                            
NSTEMI <3.3-18.9 mIU/L,                                            
controls <3.3-4.8 mIU/L 
Possible 
Sanchis                                     
et al. (2008) 
422 cTnI neg.                             
NSTE-ACS 
12-24 h after 
admission 
DSL  1.2 [0.6,2.5] mIU/L Possible 
Schoos                                       
et al. (2008) 
19 STEMI                      
(17 with PCI),                           
13 high risk NSTE-
ACS, 8 low-risk 
NSTE-ACS 
 2 h after PCI or 
at admission 
Rossen Median peak values in STEMI 
PCI patients 23.2 mIU/L,                                             
high-risk NSTE-ACS 15.3 mIU/L, 
low-risk NSTE-ACS 6.35 mIU/L 
Possible 
a Abbreviations not appearing outside this table in the thesis: ACP, acute chest pain; BDL, below detection limit; CHF, 
chronic heart failure; hs cTnI, cTnI measured with a high sensitivity cTnI assay; NCCP, non-cardiac chest pain; SEM, 
standard error of the mean; TL, thrombolysis 
b The assays are described in detail in table 4. 
c Concentrations are either median [25th,75th percentile], mean±SD, median{min-max} or within designated range 
Heeschen and colleagues (2005) studied a heterogeneous population of individuals who 
had arrived at the emergency room with chest pain. PAPP-A concentrations were signifi-
cantly higher in those patients who were later diagnosed with ACS during the index hospi-
talization than in those who were diagnosed with stable angina (SA) or who did not have 
coronary heart disease. Similarly, in a study by Elesber and colleagues (2007) the admis-
sion serum sample PAPP-A concentrations were higher in those intermediate to high risk 
chest pain patients who were subsequently diagnosed with ACS than in those patients who 
were diagnosed with non-cardiac chest pain. Moreover, McCann and colleagues (McCann 
et al., 2008) found higher PAPP-A levels in the admission samples of those patients with 
acute ischaemic-type chest pain who were later diagnosed with MI than in those without 
MI diagnoses. 
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Release profile 
The release profile of PAPP-A in ACS has been investigated in some studies. Qin and col-
leagues (2002b) reported on highly variable release profiles of PAPP-A in samples serially 
collected from 14 ACS patients after admission. A peak of elevation was seen in all pa-
tients. However, the time, height and duration of the elevation varied remarkably between 
individuals. No correlation was detected with myoglobin or CRP but significant association 
was seen with cTnI (r=0.419, p<0.001). In the previously mentioned study by Khosravi and 
colleagues (2002) serial samples were also available from three cardiac patients and in-
creasing PAPP-A levels were seen in all of them. However, the release profiles differed 
from those of cTnT and remarkably between patients. Lund and colleagues (2006) studied 
the PAPP-A release in 14 STEMI patients with frequent sampling. Median PAPP-A 
showed a peak at 1 h and rapidly declined within a couple of hours after this while median 
cTnI increased steadily up to 12 h. Moreover, in a larger STEMI cohort of the same study 
late PAPP-A elevation was detected in 32% of patients. The variable release profiles may 
explain why significant correlations of PAPP-A with cardiac troponins or other cardiac 
necrosis markers have been seen in some studies but not in others. 
PAPP-A elevations have also been studied in ACS patients in relation to percutaneous 
coronary intervention (PCI), i.e. balloon angioplasty treatment aimed for restoration of the 
blood flow through the blocked coronary arteries. Brügger-Andersen and colleagues (2007) 
found significantly higher PAPP-A levels in the plasma of STEMI patients immediately 
after PCI than before. In the same study, similar results were obtained with patients treated 
with thrombolysis instead of PCI when samples taken 90 min after the administration of the 
thrombolytic medication were compared to samples taken right before the treatment. Liu 
and colleagues (2008) also reported on higher PAPP-A concentrations after PCI than be-
fore in STEMI and UA patients. Schoos and colleagues (2009) noticed a peak in PAPP-A 
levels followed by an abrupt decrease after the treatment of STEMI patients with PCI. 
Moreover, in a very recent study by Furenes and colleagues (2009) elevated PAPP-A levels 
were detected after PCI in STEMI patients and the concentrations decreased rapidly subse-
quently. In the same study PAPP-A levels were also seen to increase significantly from the 
levels determined before the operation in SA patients treated with PCI. 
Risk prediction 
Elevated PAPP-A levels measured during index hospitalization have been shown to predict 
adverse cardiac events in ACS patients. In a study by Lund and colleagues (2003) in which 
cTnI negative ACS patients were followed for 6 months, a PAPP-A level >2.9 mIU/L 
measured within 24 h of admission predicted adverse cardiac events (new MI, death or 
revascularization) with an adjusted risk ratio of 4.6 [95% CI 1.8-11.8, p=0.002]. Similarly, 
in a study conducted by Heeschen and colleagues (2005) with angiographically confirmed 
ACS patients who were followed for 6 months, PAPP-A levels above 12.6 mIU/L in the 
first available sample predicted death and MI with an adjusted odds ratio of 2.44 [95% CI 
1.43-4.15, p=0.001]. Moreover, when only those patients with cTnT below <0.01 µg/L 
were considered, the adjusted odds ratio increased to 3.97 [95% CI 1.24-12.68, p=0.016]. 
In the same study in a heterogeneous group of chest pain patients PAPP-A levels above 7.0 
mIU/L predicted the risk for death and MI with an adjusted odds ratio of 3.08 [95% CI 
1.85-5.02, p<0.001]. In the study by Laterza and colleagues (2004) the risk of patients with 
ACS symptoms of developing ACS within 30 days was with PAPP-A levels above 0.22 
mIU/L counted to a risk ratio of 4.7 [95% CI 2.2-9.8]. However, for use of PAPP-A as a 
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discriminating marker the area under the curve from receiver-operating curve analysis in 
this study was only 0.56 [95% CI 0.50-0.61] implying insignificant discrimination power.  
Kavsak and colleagues (2009) analysed the ability of PAPP-A to predict the long-term risk 
for adverse cardiac events in patients with suggestive cardiac ischemia. Patients in the 
highest PAPP-A tertile were at higher risk for death within 2 years (p=0.03) and 10 years 
(p=0.05) even after adjusting for age, gender and baseline cTnI. Among the patients with 
cTnI below 0.04 µg/L but changing cTnI analysed with a high sensitivity cTnI assay, pa-
tients in the third PAPP-A tertile had higher probability of death (p=0.02). Moreover, in the 
study by Lund and colleagues (2006), PAPP-A was shown to predict risk for adverse 
events also in STEMI patients as the cumulative risk in 12 months was 45% in the 3rd ter-
tile of admission PAPP-A (>10 mIU/L) while the cumulative risk was only 15% in the 1st 
tertile (<3.0 mIU/L). 
Although the prognostic power of PAPP-A to predict adverse cardiac events has been 
shown in the studies presented above, others have failed to find this prognostic link. Brüg-
ger-Andersen and colleagues (2008) did not find an association between PAPP-A levels 
and adverse events in MI patients who were followed for 45 months. However, in this 
study the sampling for PAPP-A measurements was performed 4-5 days after admission 
while in the previously presented studies the sampling had been performed earlier. Simi-
larly, Sanchis and colleagues (2008) failed to show association between PAPP-A and death 
or ACS in a multivariable model when they studied patients presenting with ACS symp-
toms without ST-segment deviation or positive cTnI and followed them for 45 months. In a 
study by McCann and colleagues (2008) PAPP-A did not predict MI diagnosis in patients 
with acute ischemic-type chest pain. Moreover, in another study by the same group, 
STEMI, NSTEMI, UA and non-ischemic chest pain patients were followed for one year 
and PAPP-A was not found to be a predictor of adverse events even in an unadjusted model 
(McCann et al., 2009). However, there are doubts about the sensitivity of the assay (Ultra 
sensitive enzyme immunoassay, Demeditec Diagnostics) used in the studies of this group 
as the majority of the measured levels resided below the lowest standard (11.25 ng/mL) 
provided by the assay manufacturer (assay information from the manufacturer web page: 
http://www.demeditec.com/en/products/product_details/backPID/23/preview/papp_a_ultra
_sensitive_elisa/beginat/20/; accessed August 30, 2009). 
Molecular diagnostics 
PAPP-A has also been studied from the molecular diagnostic point of view in ACS by Park 
and colleagues (2007). Interestingly, they noticed that PAPP-A IVS6 + 95 C allele is asso-
ciated with an increased risk of MI (dominancy odds ratio 2.13 [95% CI 1.12-4.07; 
p=0.022]; codominancy odds ratio 1.89 [95% CI 1.14-3.16; p=0.015). This allele was 
found to be an independent risk factor even after adjustment for traditional risk factors. The 
single nucleotide polymorphism associated with this allele is located in an intron of the 
PAPP-A gene and the knowledge of its functional significance is lacking. However, the 
polymorphism may possibly be associated with other functional gene variants in the exons 
of the PAPP-A gene.  
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2.4.3 Other vascular diseases 
Atherosclerosis may affect arteries in various parts of the body leading to plaque formation, 
causing obstruction of the flow of blood and resulting in symptoms in the tissues affected. 
Typically, plaques form to the coronary arteries where they may lead to ACS or SA. How-
ever, the process of atherosclerosis may also lead to plaque formation in the carotid arter-
ies, thus possibly causing problems in the blood supply of the brain. A sudden rupture of a 
plaque in the carotid artery may lead to embolisation of plaque or thrombus material to the 
brain inducing transient ischemic attack or more severe ischemic stroke. Pronounced 
atherosclerosis in the lower limbs causes pain especially associated with physical exercise 
and often presents as intermittent claudication. Severe peripheral atherosclerosis may even 
lead to necrosis in the lower limbs and need for amputation.  
Coronary atherosclerosis 
Cosin-Sales and colleagues (2004) found higher PAPP-A levels in patients with complex 
coronary stenoses than in patients who did not have complex stenoses among SA patients 
undergoing angiography. The concentration of PAPP-A also correlated with the number of 
complex stenoses found in a patient. Similar associations were noticed with the ratio of 
PAPP-A concentration over proMBP concentration. In another study by the same group, 
PAPP-A levels were found to be higher in the SA patients with multi-vessel disease than in 
SA patients with single-vessel disease or without significant coronary artery stenoses 
(Cosin-Sales et al., 2005). Accordingly, the circulating PAPP-A concentrations of single-
vessel disease patients were significantly higher than those of patients without stenoses. In 
this study, PAPP-A was found to be an independent predictor of the presence of CAD. 
With a PAPP-A cut-off value of 4.5 mIU/L the sensitivity of PAPP-A for CAD prediction 
was 45% and specificity 86%. The area under the curve from receiver-operating curve 
analysis was 0.75 [95% CI 0.72-0.78]. 
PAPP-A has also been found to predict adverse cardiac events in SA patients. Elesber and 
colleagues (2006) showed that PAPP-A concentrations associated significantly in a multi-
variable model with the occurrence of death (adjusted hazard ratio 5.29 [95% CI 1.27-22.0, 
p=0.023) and the combined end-point of death and ACS (adjusted hazard ratio 3.56 [95% 
CI 1.27-10.0, p=0.015]) in a group of SA patients referred for angiography and followed 
for 4.9 years. In a study by Consuerga-Sanchez and colleagues (2008) that was conducted 
with SA patients with a median follow-up time of 8.8 years, serum PAPP-A concentration 
above 4.8 mIU/L was an independent predictor of all-cause mortality with a hazard ratio of 
1.95 [95% CI 1.14-3.36, p=0.016]. The sensitivity of PAPP-A to predict mortality at this 
cut-off concentration was 84%, but the specificity was only 33%. It is noteworthy that 
proMBP concentration and the PAPP-A over proMBP ratio were not found to be independ-
ent predictors of mortality. 
Coronary arteries severely narrowed due to extensive coronary plaque growth in SA pa-
tients are often opened by PCI, similarly to the manner in which the blocked arteries are 
opened in ACS patients. A common delayed complication of this procedure is restenosis, 
the narrowing of the artery lumen again in time. In a study by Li and colleagues (2008) it 
was shown that serum PAPP-A levels were higher 6 months after PCI in those patients in 
which restenosis was detected with angiography at that time. Thus, PAPP-A seems to be 
associated with restenosis and may also be involved in the processes leading to this com-
plication. 
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Carotid atherosclerosis 
Circulating PAPP-A levels have been associated with carotid lesions and the vulnerable 
structure of carotid plaques. Beaudeux and colleagues (2003) reported on higher circulating 
PAPP-A levels in those asymptomatic hyperlipidemic individuals who were evaluated with 
ultrasonography to have hyperechoic or isoechoic, echogenic carotid lesions, i.e. advanced 
plaques with vulnerable structure in the carotid artery, than in patients without such lesions. 
No correlation was found between PAPP-A levels and intima-media thickness, an indicator 
of the size of the carotid plaque determined ultrasonographically. Similarly, Pellitero and 
colleagues (2009) did not find a correlation between PAPP-A and intima-media thickness 
when they studied type 2 diabetes patients. However, in a study by Aso and colleagues 
(2004) a significant correlation between PAPP-A and the intima-media thickness of carotid 
plaques was shown in type 2 diabetes patients. The group of Sangiorgi (2006) revealed that 
the plasma levels of PAPP-A were higher in carotid endarterectomy patients whose re-
moved carotid plaques were vulnerable in structure or were ruptured with thrombus than in 
patients whose removed plaques were stable in structure. In the same study the plasma 
PAPP-A levels also correlated significantly with the extent of immunohistochemical stain-
ing for PAPP-A in tissue samples of the removed plaques. 
Fialová and colleagues (2006) found higher circulating PAPP-A levels in patients who had 
experienced a cerebrovascular event than in controls. When certain types of cerebrovascu-
lar events were looked at separately, the differences in PAPP-A levels compared to controls 
were significant only in patients with intrachranial haemorrhage or in ischemic stroke pa-
tients who had CAD. Patients with ischemic stroke without CAD did not have elevated 
PAPP-A levels, although ischemic stroke rather than haemorrhage is often associated with 
plaque rupture and embolisation.  
Setacci and colleagues (2008) studied patients who underwent carotid stenting to prevent 
new cerebrovascular events. Among patients who had experienced transient ischemic at-
tack or stroke they found higher post-operative than pre-operative serum concentrations of 
PAPP-A. 
Peripheral atherosclerosis 
In addition to carotid and coronary atherosclerosis, an association has also been found be-
tween circulating PAPP-A and peripheral atherosclerosis by the group of Mueller (2006). 
They noticed higher serum PAPP-A levels in patients with symptomatic peripheral arterial 
disease than in age, sex and diabetes status matched controls. In this study PAPP-A pre-
dicted peripheral arterial disease in the fourth PAPP-A quartile in a multivariable model 
with an odds ratio of 2.86 [95% CI 1.78-4.59, p<0.001].  
Hypercholesterolemia is a significant risk factor for cardiovascular diseases. Stǔlc and 
colleagues (2003) reported on higher serum PAPP-A concentrations in patients with iso-
lated cholesterolemia but without symptoms of vascular disease than in healthy controls. 
However, there was no significant correlation between PAPP-A and serum lipid levels. On 
the other hand, the group of Ceska (2003) found no difference between the serum levels of 
PAPP-A in patients with isolated cholesterolemia, in patients with combined hypercholes-
terolemia, in patients with severe but stable CAD or in patients without hypercholes-
terolemia. 
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2.4.4 Renal dysfunction 
Kidney dysfunction is generally associated with increased risk for adverse cardiovascular 
events (Hage et al., 2009). In the study by Fialova and colleagues (2004), circulating 
PAPP-A levels correlated with serum creatinine levels (r=0.68, p<0.05) in chronic haemo-
dialysis patients and with 24-h creatinine clearance (r=-0.59, p<0.05) in chronic renal in-
sufficiency patients who had not yet been dialyzed. However, the serum concentrations of 
PAPP-A were not significantly higher in these patients than in controls. Astrup and col-
leagues (2007) found elevated PAPP-A levels in type 1 diabetic patients with diabetic 
nephropathy presenting with persistent significant albuminuria when they were compared 
to matched type 1 diabetic patients with normal albumin secretion or to non-diabetic con-
trols. In diabetic nephropathy patients the glomerular filtration rate, the indicator of kidney 
function, had an inverse correlation with PAPP-A (r=-0.21, p=0.003). 
Significantly higher PAPP-A levels have been reported in end-stage renal disease patients 
undergoing haemodialysis therapy than in healthy controls (Kalousova et al., 2003; Fialova 
et al., 2004; Lauzurica et al., 2005b; Hodkova et al., 2006; Coskun et al., 2007b). Increased 
levels have also been found in peritoneal dialysis patients and haemodiafiltration patients. 
One group reported on higher PAPP-A elevations with haemodialysis than peritoneal di-
alysis (Fialova et al., 2004), while others have shown similar elevations with different di-
alysis modalities (Kalousova et al., 2006; Coskun et al., 2007b). The levels of PAPP-A 
have been shown to remain unchanged (Fialova et al., 2004; Kalousova et al., 2006) or 
slightly increase (Coskun et al., 2007b) when PAPP-A concentrations before the dialysis 
session have been compared to levels measured at 4 h after beginning the dialysis. How-
ever, more detailed sampling revealed a significant increase in plasma PAPP-A at 15 min 
and decrease thereafter during the haemodialysis session and a similar effect was seen with 
the heamodiafiltration procedure (Hodkova et al., 2005; Kalousova et al., 2006). Correla-
tions have been found in haemodialysis patients between PAPP-A and advanced oxidation 
protein products (Kalousova et al., 2003), CRP (Fialova et al., 2004), cytokines IL-6 and 
TNFα (Lauzurica et al., 2005a), F2-isoprostanes as markers of oxidative stress (Lauzurica 
et al., 2005b), intact parathyroid hormone, alkaline phosphatase activity and dialysis ther-
apy duration (Coskun et al., 2007c). In haemodialysis patients serum PAPP-A has been 
shown to associate with higher mortality rates (Kalousova et al., 2004). 
Elevated PAPP-A levels have also been found in renal transplant patients when compared 
to healthy controls (Coskun et al., 2007c). However, serum PAPP-A concentrations have 
been shown to decrease after kidney transplantation (Kalousova et al., 2007). In renal 
transplant patients PAPP-A correlates inversely with glomerular filtration rate (r=-0.52, 
p<0.001) (Kalousova et al., 2007). Moreover, significant correlations with PAPP-A have 
been reported in transplant patients with urea (r=0.547, p=0.001), creatinine (r=0.497, 
p=0.001), uric acid (r=0.452) and CRP (r=0.387, p=0.001) (Coskun et al., 2007c). How-
ever, other studies revealed no correlation with CRP (Kalousova et al., 2007) or creatinine 
(Lauzurica et al., 2005a). In a graft biopsy taken 3 months after transplantation serum 
PAPP-A levels seemed to associate with histological findings of interstitial inflammation 
(r=0.57, p<0.05) and vascular fibrous intimal thickening (r=0.47, p<0.05) possibly imply-
ing a worse fate for the graft (Kalousova et al., 2007). 
Delayed graft function, new-onset diabetes mellitus after transplantation (NODAT) and 
chronic allograft nephropathy are frequent complications after renal transplantation. Serum 
PAPP-A levels in samples taken 1-3 h before kidney transplantation were not significantly 
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higher in those non-diabetic patients who developed NODAT than in those who did not 
develop NODAT within a mean follow-up time of 5.7 months (Bayes et al., 2007). How-
ever, in a study by Lauzurica and colleagues (2008) significantly higher PAPP-A concen-
trations were measured 6-8 h before renal transplantation in those patients who developed 
delayed graft function within the first week after transplantation than those who did not. 
Additionally, in a multivariate analysis PAPP-A was identified as an independent risk fac-
tor of delayed graft function with an odds ratio of 2.96 [95% CI 1.34-5.40]. PAPP-A in 
serum samples taken 6-8 h before renal transplantation predicted chronic allograft neph-
ropathy with a risk ratio of 4.27 [95% CI 1.03-17.60] (Lauzurica et al., 2005a). Moreover, 
in the same study PAPP-A was also an independent predictor of post-transplant 
cardiovascular events with a risk ratio of 6.4 [95% CI 1.23-33.11]. 
2.4.5 Other conditions 
Some studies have evaluated the levels of PAPP-A in blood in other conditions than those 
already presented above. Pellitero and colleagues (2007) found higher circulating PAPP-A 
levels in type 2 diabetes mellitus patients with stable glycaemic control and without 
macrovascular disease than in matched controls. Interestingly, in these diabetic patients 
serum PAPP-A concentrations correlated inversely with HbA1c, the indicator of haemo-
globin glycosylation (r=-0.2, p=0.03). Coskun and colleagues (2007a) reported on higher 
serum PAPP-A levels in patients with newly diagnosed asthma and without anti-
inflammatory medication than in healthy controls. In this study a correlation was also 
found between serum PAPP-A and the severity of asthma (r=0.581, p<0.01). In the study 
by Bulut and colleagues (2009) the serum PAPP-A levels were found to be higher in lung 
cancer patients than in age, sex and smoking history matched controls. However, no differ-
ences were seen between different cancer forms (small cell carcinoma, epidermoid carci-
noma, or adenocarcinoma). In the lung cancer patients serum PAPP-A levels correlated 
inversely with the Karnofsky performance status, the indicator of the functional status of 
the patient (r=-0.330, p<0.001).  
Rysava and colleagues (2007) found no differences in serum PAPP-A levels between pa-
tients with rheumatological diseases and histologically proven amyloid A amyloidosis, 
patients with rheumatoid arthritis but without amyloidosis and healthy controls. Moreover, 
in a study by Iversen and colleagues (2008a) no differences in mean PAPP-A serum con-
centrations were detected between patients with certain diagnoses among 1448 consecutive 
patients admitted to hospital with diagnoses other than ACS.  
2.4.6 Effect of medication 
Heparin 
When using PAPP-A as a marker measured in the blood, it is imperative to know how dif-
ferent medications affect the circulating levels to avoid confounding effects and to discover 
the possible beneficial or harmful influence of certain medication schemes. 
As discussed previously, it has been shown in in vitro studies that PAPP-A is able to bind 
to cell surfaces by attaching to glycosaminoglycans, presumably heparan sulfate, with its 
GAG binding site located at the CCP3 and CCP4 domains of PAPP-A (see section 2.1.2) 
(Laursen et al., 2002b). The binding can be reversed by heparan sulphate or heparin GAGs 
(Laursen et al., 2002b). Westergaard and colleagues (1983b) have shown the direct interac-
tion of PAPP-A with heparin which can be reversed with specific heparin antagonist pro-
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tamine sulphate. Heparin-binding alters the electrophoretic mobility of PAPP-A and leads 
to dose-dependent artificial increase in the concentrations of PAPP-A measured with elec-
troimmunoassay implying dose-dependent change in the molecule (Westergaard et al., 
1983b). 
GAGs are heterogenous polysaccharides in terms of their molecular mass, charge, density 
and physico-chemical properties as they are not synthesized as homologous copies of tem-
plates. In the human body, heparin is found primarily in the mast cells and it resembles 
heparan sulphate in structure. Its most prominent constituent is a disaccharide of sulphated 
L-iduronic acid and sulphated D-glucosamine. (Reviewed by Korir and Larive, 2009.) 
Due to their anticoagulative effects, heparin products are widely used in the treatment of 
patients in whom blood coagulation should be prevented. Unfractionated heparin (UFH) is 
usually recovered from porcine instestines and is always a mixture of molecules of differ-
ent structures and molecule sizes. The mixture consists of mucopolysaccharide molecules 
with a molecular weight ranging from 3 000 to 30 000 composed of alternating sulfated 
disaccharide units. The sulfated groups give heparin a highly negative charge. UFH inhibits 
blood coagulation by catalyzing the reaction between antithrombin III (ATIII) and throm-
bin, thus inhibiting the conversion of soluble fibrinogen to blood clot forming fibrin. The 
inhibition of thrombin by ATIII also requires binding of the same heparin molecule to 
thrombin. In addition, heparin binding to ATIII leads to inactivation of factor Xa of the 
coagulation cascade. (Reviewed by Davenport, 2008.) 
Low molecular weight heparins (LMWH) can be produced through chemical or enzymatic 
degradation of UFH to shorter polysaccharides (Korir and Larive, 2009). The average mo-
lecular weight varies from 4200 to 6000 between products. LMWH are not long enough to 
also bind thrombin when attached to ATIII and their anticoagulation activity is thus medi-
ated only through inactivation of factor Xa. The half-life of LMWHs in human circulation 
varies between different products but is generally significantly longer than that of UFH due 
to differences in the metabolic routes. (Reviewed by Davenport, 2008.)  
Heparin administration has been shown to increase rapidly and significantly the concentra-
tion of certain molecules in the circulation. For example, in a study by Jones and col-
leagues (2004) UFH elicited a rapid and dose-dependent release of activin A and follistatin 
in the circulation of adult female sheep. Multiple administration of heparin led to repeated 
responses to each injection, but the subsequent stimulation increased and extended the 
responses, consistent with saturation of the heparin clearance mechanism. The rapidity of 
the release, within 5 min, suggested a release from the luminal surface of the vascular en-
dothelium directly into the circulation. Similarly, a rapid and robust release of activin A 
and follistatin into the circulation at the time of vessel clamping and administration of UFH 
(5000 IU) was shown by Phillips and colleagues (2000) in patients who were undergoing 
abdominal aortic aneurysm repair or carotid endarterectomy. The peak concentrations were 
reached at 5-15 min after the clamping of the artery and heparin administration. Moreover, 
in the same study, administration of heparin (2500 IU) to coronary angiography patients 
produced a similar activin A and follistatin response.  
In a study by Baldus and colleagues (2006) heparin administration has also been shown to 
affect the circulating levels of a candidate molecule for a new ACS marker, myeloperoxi-
dase (MPO). Plasma concentrations of MPO increased significantly in patients who under-
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went coronary angiography with UFH bolus administration (70 U/kg), approximately 1.6-
fold at 15 min after administration. The increase was higher in patients with CAD (p=0.01) 
than in patients without detectable CAD. Moreover, in the same study, ex vivo heparin 
treatment of extracellular matrix proteins, cultured endothelial cells and saphenous vein 
graft specimens from CAD patients resulted in MPO release to the surrounding solution 
implying that MPO was released into the circulation from the blood vessel wall.  
Terkelsen and colleagues (2009) have reported preliminary evidence that heparin may also 
affect the circulating concentrations of PAPP-A. In their study, plasma PAPP-A levels 
were compared between 84 STEMI patients, who received UFH (10 000 U) and were 
treated with PCI before or after sampling, and 14 STEMI and 56 NSTEMI patients who 
were not given UFH or any other medication before sampling. The PAPP-A levels in the 
plasma samples tended to be higher in the group of STEMI patients with UFH and PCI 
treatment than in the STEMI patients without UFH and PCI treatment (median 18 [25th,75th 
percentile: 5.8,40] vs. 5.5 [3.7,24] mIU/L, p=0.07). Plasma PAPP-A levels were signifi-
cantly higher in the STEMI patients with UFH and PCI treatment than in the NSTEMI 
patients (5.2 [3.4,7.0] mIU/L, p<0.001). However, the exact timing information of the 
heparin administration in relation to sampling was lacking. Moreover, samples before and 
after heparin administration taken from the same individuals were not available. In the 
group of STEMI patients with UFH and PCI, PAPP-A seemed to be cleared from the circu-
lation within a few hours after onset of symptoms or treatment with PCI.  
In the same study Terkelsen and colleagues showed that injection of human recombinant 
PAPP-A in mice with concomitant UFH administration resulted in higher circulating 
PAPP-A peak levels than without UFH and in delayed recombinant PAPP-A clearance. 
When UFH administration was delayed for 5 min after PAPP-A administration, re-
elevation in circulating PAPP-A concentration was seen, implying that heparin may possi-
bly facilitate PAPP-A detachment from the vessel wall.  
The finding that heparin products may affect circulating PAPP-A concentration is espe-
cially important in that the results of previous studies may have been biased by heparin 
medication. UFH and LMWH are widely used in the treatment of ACS patients (Mahaffey 
et al., 2005). The likelihood of bias caused by heparin for all ACS related PAPP-A studies 
published thus far is estimated in Table 3. However, studies with non-ACS patients may 
have also been affected by the heparin effect as, for example, UFH or LMWH are generally 
used to prevent blood clotting during dialysis sessions (Davenport, 2008).  
Other medication 
The effect of certain other medications on circulating PAPP-A concentrations has also been 
under investigation. It has been reported that the use of atorvastatin (20 mg/day) for 10 or 
12 weeks did not affect serum PAPP-A levels in isolated cholesterolemia patients although 
significant decrease was seen in LDL, total cholesterol and CRP levels (Ceska et al., 2003; 
Stulc et al., 2003). Similarly, in a study by Pellitero and colleagues (2007) no association 
was found between the concentration of circulating PAPP-A and statin use in type 2 diabe-
tes patients. However, Miedema and colleagues (2008) showed a borderline significant 
(p=0.05) decrease in PAPP-A levels in ACS and stable CAD patients after use of atorvas-
tatin (80 mg/day) for 1 month. A lower dose of 10 mg/day did not have a similar effect.  
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The use of fenofibrates in patients with combined hyperlipidemia caused no changes in 
serum PAPP-A levels and neither did LDL-apheresis in patients with hypercholesterolemia 
and severe but stable CAD (Stulc et al., 2003). However, in a population of >80 years old 
hypertensive individuals PAPP-A was significantly lower in those who took calcium chan-
nel blockers to reduce hypertension than in those without this medication (Onder et al., 
2007). In patients undergoing off-pump coronary artery bypass graft surgery, there was a 
significant increase in PAPP-A blood levels measured at 72 h after the procedure in pa-
tients who received the intravenous anaesthetic propofol although with anaesthetic gas 
sevoflurane treatment the levels mildly decreased (Lucchinetti et al., 2007). The effects on 
PAPP-A concentrations are currently unknown for other drugs often given to CAD or ACS 
patients, such as acetylsalicylic acid, β-blockers, clopidogrel, glycoprotein IIb/IIIa inhibi-
tors, inhibitors of angiotensin-converting enzyme and nitrates. 
Intravenous iron is given to haemodialysis patients to enhance the response to erythropoi-
etin therapy aimed for preventing kidney failure and dialysis induced anaemia. Hodkova 
and colleagues (2005) noticed that intravenous iron given during haemodialysis session 
increased and prolonged the previously found PAPP-A elevation during the dialysis ses-
sion. In kidney transplant patients, immunosuppressive medication is invaluable in prevent-
ing rejection reactions against the renal graft. No differences were found in the circulating 
concentrations of PAPP-A between the transplantation patients using cyclosporine mi-
croemulsion or tacrolimus for immunsuppression (Lauzurica et al., 2007). Similarly, 
Coskun and colleagues (2007c) found no effect of immunosuppressive drugs on PAPP-A 
serum levels in renal transplant patients. It has also been noticed that vitamin E, a potent 
antioxidant, did not change the serum levels of PAPP-A within 5 weeks of oral therapy 
(400 mg / day) in haemodialysis patients (Hodkova et al., 2006). 
Finally, Jones and Clemmons (1995) noticed that circulating levels of PAPP-A are higher 
in growth hormone deficient adults than in matched control subjects. However, one year of 
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3 AIMS OF THE STUDY 
The overall aim of this thesis was to study the novel ACS-associated biomarker, PAPP-A. 
As an ACS-related form of PAPP-A was identified, the further aims were to develop an 
easy and rapid detection method for this molecule and to evaluate analytical and clinical 
performance of the method. In addition, we also studied how the heparin products com-
monly used as medication in ACS patients affect the PAPP-A molecule and the circulating 
concentrations of PAPP-A forms. 
More specifically the aims were: 
I To characterize the PAPP-A forms present in the circulation of ACS patients. 
II To develop a point-of-care detection method for the ACS-related form of PAPP-A 
and to evaluate the performance of the method in serum and heparin plasma. 
III To evaluate the performance of the developed point-of-care method in the detection 
of the ACS-related form of PAPP-A in heparinized whole blood. 
IV To evaluate the clinical performance of the ACS-related form of PAPP-A measured 
by the developed detection method as a risk marker predicting adverse cardiac 
events in ACS patients. 
V To investigate the effect of treatment with intravenous heparin products on the circu-
lating concentrations of PAPP-A forms. 
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4 SUMMARY OF MATERIALS AND METHODS 
The detailed descriptions of the materials and methods used in this study can be found in 
the original publications (I-V). A brief summary with some additional information is pre-
sented here. 
4.1 Clinical samples and standard materials 
The sample panels used in the studies (I-V) are described in Table 4. All samples were 
collected after informed consent of the donor and the study protocols were in conformance 
with the Declaration of Helsinki as revised in 1996. The serum and plasma samples were 
stored at -20 °C (pregnancy serum) or at -70 °C (other samples). Heparinized whole blood 
samples were used freshly. 




Study population Gender 
(males/ 
females) 




Publication and use 
8 STEMI 
patients 
4/4 males        
63 (13),  
females     
72 (16) 
Admission; 1, 
2, 4, 6, 24 and 
48 h  
serum I Study of PAPP-A 







12, 24 and 48 
h; discharge 
serum II Developed total 
PAPP-A assay vs.an 
older total PAPP-A 
assay 
TUCH                      
2000-2001 





267        





12 and 24 h  
serum IV free PAPP-A as a 
prognostic biomarker 
in ACS patients 
HUCH                
2004-2005 
39 STEMI patients 26/13 62 
[56,70] 
Prehospitally; 
before PCI; 0, 






II Serum vs. heparin 
plasma as sample 
matrices,              
total PAPP-A assay 
evaluation 
TUCH                 
2007-2008 




62 (9) Before; 5, 15 
and 120 min 
(+20, 30, 60, 
125, 135 or 240 
min from some 
patients)  
serum V LMWH effect on 
circulating PAPP-A 
concentration 
TUCH                          
2007-2008 
10 angiography patients 5/5 65 (15) Before; 5 and 
15 min; at the 
end  
serum V UFH effect on 
circulating PAPP-A 
concentration 
3            0/3 - Gestational age 
9, 10 or 11 
weeks  
serum I Study of PAPP-A 
forms in serum 








3           0/3 - Gestational age 
5, 8 or 9 weeks  
serum II Complexed PAPP-A 
assay evaluation 












III Heparinized whole 
blood as the sample 
matrix  
a HUCH, Helsinki University Central Hospital, Finland; Labquality, Finland (a commercial panel); SSI, Statens 
Serum Institut, Denmark; TUCH, Turku University Central Hospital, Finland; UTU-DB, University of Turku / 
Department of Biotechnology, Finland 
b Ages presented as mean (standard deviation), median [25th ,75th percentile] or range 
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A pool of third trimester pregnancy sera diluted in a buffer containing 0.05 mol/L Tris-HCl 
pH 7.75, 0.15 mol/L NaCl, 0.5 g/L NaN3 and 60 g/L bovine serum albumin (BSA) was 
used as the standard material for the PAPP-A assays (I-V). BSA was either from Intergen 
(Millipore, USA) or Sigma-Aldrich (USA). The standard material was calibrated against 
the pooled third-trimester pregnancy serum-derived WHO IRP 78/610 standard for preg-
nancy-associated proteins (WHO International Laboratory for Biological Standards, Stat-
ens Serum Institut, Copenhagen, Denmark). The standard solutions were stored at -20 °C 
until use.  
4.2 Recombinant PAPP-A 
The recombinant human PAPP-A used in publication III and in some unpublished experi-
ments described here was produced in human embryonic kidney 293T cells which were 
transiently transfected with pFLAG-CMV-1 plasmid containing the coding sequence of the 
whole human PAPP-A. The plasmid was a generous gift from Dr. Xuezhong Qin from J. L. 
Pettis Memorial Veterans’ Medical Center, Loma Linda, USA. The transfection was con-
ducted according to the instructions of the transfection reagent manufacturer using a ratio 
of 1 µg of plasmid DNA and 6 µL of FuGENE® 6 transfection reagent (Roche Diagnostics, 
Switzerland). The cells were grown in DMEM culture medium supplemented with 100 
mL/L fetal bovine serum. The supernatant was collected 8 days after transfection, cleared 
by centrifugation and stored at -20 °C until use.  
4.3 Antibodies  
In the studies the six monoclonal IgG antibodies (B1-B6) used were created through im-
munisation of mice with PAPP-A/proMBP complex and were a kind gift from Dr. Michael 
Christiansen from Statens Serum Institut, Copenhagen. Eleven monoclonal antibodies (A1-
A11) similarly developed were received from HyTest Ltd., Finland. 
Antibodies used for detection in the immunoassays were labeled with a heptadentate euro-
pium chelate ({2,2´,2´´,2´´´-{[4-[(4-isothiocyanatophenyl)ethynyl]pyridine-2,6-diyl]-bis 
(methylenenitrilo)}tetrakis(acetato)}europium(III)) (Takalo et al., 1994) (I) or with a non-
adentate α-glucose europium chelate ({2,2´,2´´,2´´´-{[2-(4-isothiocyanatophenyl)ethyl 
imino]bis(methylene)bis{4-{[4-(α-glucopyranoxy)phenyl]ethynyl}-pyridine-6,2-diyl}bis 
(methylenenitrilo)}tetrakis(acetato)}europium(III)) (von Lode et al., 2003) (II, III, IV, V). 
These inherently fluorescent chelates and the biotinylation reagent, biotin isothiocyanate, 
were kindly provided by Jaana Rosenberg (University of Turku, Finland). 
The labeling reactions are described in detail in original publications I and II. In brief, 15- 
to 100-fold molar excess of Eu3+ chelate over the antibody was used in the reaction con-
taining 1 mg/mL antibody in 0.05 mol/L Na2CO3/NaHCO3 buffer, pH 9.6. Ethylene glycol 
in the concentration of 100 mL/L was also included in some reactions to enhance the label-
ling efficiency (II). The Eu-labeling reactions were incubated overnight at room tempera-
ture in the dark. Antibody biotinylations were conducted with 1 mg/mL antibody concen-
tration in 0.05 mol/L Na2CO3/NaHCO3 buffer, pH 9.6, with 15- to 50-fold molar excess of 
biotin isothiocyanate over the antibody by incubating for three hours at room temperature 
in the dark. The labeled antibodies were separated from free chelate or biotin isothiocy-
anate by gel filtration using a buffer containing 0.15 mol/L Tris-HCl (pH 7.75), 0.15 mol/L 
NaCl, and 0.5 g/L NaN3 for elution. The labeled antibodies were stabilized with 1 g/L BSA 
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and stored at 4 °C. Typically, 5 to 15 Eu3+ chelates became attached to each antibody 
molecule in the labeling procedure. 
4.4 Immunoassays 
4.4.1 Manual assays 
For the immunoassays conducted by manual pipetting (I), low-fluorescence 96-well plate 
microtitration wells (NUNC, Denmark) were coated with the capture antibody either 
through passive interaction of 400 ng of antibody per well (I, details in Qin et al., 2001) or 
through binding of 100 - 300 ng of biotinylated antibody in 50 µL of assay buffer (I, details 
in Pettersson and Soderholm, 1990) in each microtitration well previously coated with 
streptavidin (Innotrac Diagnostics). 
After washing with wash solution (I, details in Pettersson and Soderholm, 1990) sample or 
calibrator and 100 - 300 ng of detection antibody in assay buffer or in modified assay 
buffer (containing 0.1 g/L denatured mouse IgG and 0.2 g/L native mouse IgG) in a total 
volume of 30 µL were added to the wells. The wells were incubated for 30 - 60 minutes at 
36 °C with 900 rpm shaking in iEMS shaker/incubator (Labsystems, Finland), washed six 
times with wash solution, dried under a stream of 60 °C air for 5 min and allowed to cool at 
least for 5 min. The time-resolved europium fluorescence was measured from the dry-
surface with a Victor™ 1420 multilabel counter (PerkinElmer; Wallac, Finland). 
4.4.2 Automated assays in all-in-one dry-cups 
To prepare all-in-one dry-cups (II), 300 ng of biotinylated capture antibody in 50 µL of 
assay buffer was immobilised in streptavidin coated single-wells (Innotrac Diagnostics) 
overnight at ambient temperature. After washing, 40 µL of a protective solution was added 
to the wells and dried overnight at 35 °C and 5% relative humidity. Europium-labeled de-
tection antibody (200 - 300 ng per well) was added in 1 µL of optimized label diluent 
buffer (von Lode et al., 2003) on top of the insulating layer and dried immediately in a 
stream of hot air. The dry-reagent wells were packed in analyte pens and stored at 4 °C 
protected from humidity until use. The calibrator wells were prepared otherwise similarly 
but a known concentration of PAPP-A calibrator was added to the protective solution. 
The assays were performed with an automated Aio! Immunoanalyzer with a protocol ap-
plying in each dry-cup 20 µL of sample and 10 µL of Aio! buffer (Innotrac Diagnostics). 
The instrument incubated the cups at 36 °C for 15 minutes with shaking and, after washing 
for six times and drying the cups, time-resolved fluorescence was measured from the sur-
face of the cup. The concentrations of samples were obtained from the analyzer as it com-
pared the fluorescence signals against a calibration curve constructed by the instrument 
with the calibrator wells. 
4.5 Gel filtration studies   
In gel filtration studies samples were fractionated with a Superose 6 PC 3.2/30 gel filtration 
column (GE Healthcare Life Sciences, UK) operated with the SMART system (GE Health-
care Life Sciences) at 10 °C. A buffer containing 0.05 mol/L Na2HPO4/NaH2PO4, 0.15 
mol/L NaCl and 0.2 g/L NaN3, pH 7.0 (gel filtration buffer) was used for the equilibration 
of the column and the elution at a flow rate of 40 µL/min. The samples were filtered 
through 0.45 µm and 0.22 µm filters and diluted two-fold in the gel filtration buffer prior to 
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the injection to the column. Fractions were collected between elution volumes 0.6 mL and 
2.8 mL (100 µL fractions) or 0.9 mL and 1.9 mL (25 µL fractions) and analysed immedi-
ately.  
4.6 Studies with heparin products  
The effect of heparin products on the circulating levels of PAPP-A was studied with 14 
haemodialysis patients and with 10 CAD patients who underwent elective coronary an-
giography (IV). The coronary angiography patients received UFH (LEO®, LEO Pharma, 
Denmark) at the start of the procedure as an intravenous bolus of 5000 IU. One patient was 
treated with PCI and thus received additional UFH boluses. The haemodialysis patients 
received enoxaparin (Klexane®, Sanofi-Aventis, Belgium), an LMWH widely used in 
haemodialysis treatment to prevent extracorporeal circuit clotting (Davenport, 2008). Fol-
lowing the standard patient care at Turku University Central Hospital, 40 to 60 mg of 
LMWH was administered intravenously in the dialysis line at the start of the dialysis ses-
sion. In four of the patients with increased risk of bleeding, a heparin-free dialysis protocol 
was used. Two of these patients received a reduced LMWH bolus (20 mg) at 2 h after the 
start of the procedure. 
Studies were also conducted in which enoxaparin and UFH in concentrations approximat-
ing those of treated patients (8.5 mg/L and 1.1 mIU/L, respectively) were added to whole 
blood samples of haemodialysis patients which were anticoagulated by citrate, EDTA, Li-
heparin (standard blood collection glass vacuum tubes from Venoject®, Terumo Europe) or 
hirudin (recombinant hirudin 2 µg/mL, America Diagnostica, USA) (IV). 
In addition, gel filtration studies were performed with recombinant PAPP-A in gel filtration 
buffer, serum or heparin plasma of a healthy individual or in serum in which enoxaparin (2 
mg/mL) was added (unpublished). Serum and heparin plasma from ACS patients were 
also compared with pregnancy serum by gel filtration (unpublished). 
4.7 Statistical analyses 
Statistical analyses (II, III, IV, V) were performed with statistical softwares SAS version 
9.1 or 9.2 with SAS Enterprise guide 3.0 (SAS institute, USA) and GraphPad Prism for 
Windows version 4.02 (GraphPad Software Inc., USA). All p values were reported 2-tailed 
and p values <0.05 were considered significant. The normality of the distribution of the 
values of each continuous variable was determined by the Kolmogorov-Smirnov test, the 
shape of the distribution and the probability plots. Pearson correlation was used to assess 
the linear correlation of continuous variables. Spearman rank-correlation was used with the 
variables with non-gaussian distribution. The Mann-Whitney U-test test was utilized for 
assessing the differences between groups with non-normally distributed continuous vari-
ables and the Student t-test with normally distributed continuous variables. Wilcoxon 
signed rank test with Bonferroni correction was used when comparing the levels of a con-
tinuous variable in samples taken from patients at different time points. Categorical vari-
ables were compared between groups with the Chi-Square test. The multivariate associa-
tions were analysed using Cox’s proportional-hazards model. 
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5 SUMMARY OF RESULTS 
5.1 PAPP-A forms  
5.1.1 ACS patients (I, II) 
The concentration of PAPP-A was found to be elevated in the circulation of ACS patients 
in 2001 (Bayes-Genis 2001). However, pronounced fluctuations in the concentration were 
detected in serial samples collected from ACS patients (Qin et al., 2002b). Therefore, we 
tested various antibody combinations in order to detect possible blood borne degradation or 
complexation products of PAPP-A in serial serum samples of ACS patients. Although no 
such products were found, it was noticed that, in the samples showing elevated PAPP-A 
levels with assays using PAPP-A reactive antibodies, antibodies reactive with the proMBP 
subunit of the PAPP-A/proMBP complex did not detect this elevation. 
Based on the epitope map that was constructed with the available monoclonal antibodies, 
assays were designed to specifically detect all molecules with PAPP-A subunits (Assays T 
(I), total PAPP-A assay (II, III, IV, V)) or PAPP-A only in complex with proMBP (Assay 
C (I), PAPP-A/proMBP assay (II, III, IV), complexed PAPP-A assay (V)) (Fig. 9). Sig-
nificant concentration elevation was only detected in ACS samples with the total PAPP-A 
assay while the low levels detected with the complexed PAPP-A assay remained stable 
(Fig. 10A). Moreover, the correlation between the total PAPP-A and complexed PAPP-A 
levels detected in a large panel of serum samples from ACS patients was not strong (r = 
0.532) (Fig. 10B). 
 
 
Figure 9. The principle of the assays designed for total PAPP-A and complexed PAPP-A detection. The 
capture antibody in both assays binds to the PAPP-A subunit. Thus, all PAPP-A subunit containing mole-
cules in the sample become attached to the surface. In total PAPP-A assay the labeled detection antibody 
binds to the PAPP-A subunit at a separate epitope. Subsequently, all PAPP-A subunit containing mole-
cules whether or not complexed with proMBP are detected. In complexed PAPP-A assay the labeled 
detection antibody binds to the proMBP subunit and thus only the PAPP-A/proMBP complex is detected. 
The concentration of free PAPP-A is determined by calculating the difference of the results given by these 
two assays. The labeled antibodies are labeled with europium chelates (Eu) which enable signal detection 
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Figure 10. Total PAPP-A and complexed PAPP-A in ACS patients. A) The concentrations of total PAPP-
A and complexed PAPP-A of serial serum samples collected from an ACS patient at certain time points 
after the onset of symptoms. B) Correlation of the total PAPP-A concentrations and the complexed PAPP-
A concentrations in 651 serum samples of 200 ACS patients (r = 0.532).  
 
With gel filtration studies it was revealed that the molecular weight of the PAPP-A form 
causing the elevation in the total PAPP-A assay signal in ACS patient serum also differed 
from the molecular weight of PAPP-A in pregnancy serum. PAPP-A in pregnancy serum 
eluted earlier from the gel filtration column than PAPP-A in ACS serum implying that 
PAPP-A in pregnancy serum was larger in molecular size. The PAPP-A form in fraction-
ated pregnancy serum was equally detectable by the total PAPP-A and complexed PAPP-A 
assays, while the PAPP-A form in fractionated ACS serum was not detected by the com-
plexed PAPP-A assay. 
5.1.2 Healthy individuals (II) 
We found, in an apparently healthy population, the total PAPP-A median level to be 2.4 
[25th,75th percentile: 2.0,3.1] mIU/L and the 97.5th percentile upper reference limit to be 4.9 
mIU/L (Fig. 11). Detected median complexed PAPP-A concentration was 2.2 [1.8,3.0] 
mIU/L and the median free PAPP-A concentration was 0.2 [-0.16,0.47] mIU/L in the same 
population (Fig. 11). The 97.5th percentile upper reference limit for free PAPP-A was 1.3 
mIU/L. A weak but statistically significant correlation was found between total PAPP-A 
concentration and age (r=0.290, p<0.001) and complexed PAPP-A and age (r=0.230, 
p=0.004). However, such a correlation was not found between free PAPP-A and age 
(r=0.075, p=0.348). Total PAPP-A and free PAPP-A concentrations were significantly 
higher in men than in women (total PAPP-A men 2.8 [2.4,3.5] mIU/L vs. women 2.1 
[1.7,2.5] mIU/L, p<0.001; free PAPP-A men 0.28 [0.0,0.7] mIU/L vs. women 0.04 [-
0.2,0.6] mIU/L, p=0.003). 
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Figure 11. Distribution of total PAPP-A, complexed PAPP-A and free PAPP-A in a population of 159 
apparently healthy non-pregnant individuals. (The top and bottom whiskers indicate the minimum and 
maximum concentration; the other horizontal lines represent the 25th, 50th and 75th percentiles.) 
 
5.2 Point-of-care assays for free PAPP-A measurement 
5.2.1 Evaluation of analytical performance (II, III) 
To enable easy and rapid determination of free PAPP-A, time-resolved immunofluoromet-
ric point-of-care assays were developed for total PAPP-A and complexed PAPP-A. The 
concentration of free PAPP-A was calculated from the results given by these assays by 
subtracting the measured complexed PAPP-A concentration from the measured total 
PAPP-A concentration.  
The analytical performance characteristics of the developed assays are shown in Table 5. 
Both assays gave linear signal response with the pregnancy serum derived calibrators di-
luted in buffer as well as with ACS and 1st trimester serum samples in the range relevant in 
the context of ACS samples, 0-300 mIU/L. ACS serum was used for the evaluation of the 
total PAPP-A assay. However, the evaluation of the complexed PAPP-A assay was mainly 
conducted with pregnancy serum because the concentration of complexed PAPP-A in ACS 
serum is generally low (<5 mIU/L). There was a good agreement between the concentra-
tions measured from serum samples and respective heparin plasma samples collected from 
STEMI patients (Table 5). The assays also performed well when evaluated with 
heparinized whole blood samples from apparently healthy individuals into which either 
recombinant PAPP-A as surrogate of the free PAPP-A in ACS serum (total PAPP-A assay) 
or third trimester pregnancy serum containing complexed PAPP-A (complexed PAPP-A 
assay) was added (Table 5).  
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Table 5. Analytical performance characteristics of the developed assays for total PAPP-A and complexed 
PAPP-A. 
    Total PAPP-A assay Complexed PAPP-A assay 
Analytical detection limit (II)a 0.18 mIU/L 0.23 mIU/L 
Functional detection limit (II)b 0.27 mIU/L 0.70 mIU/L 
Recovery in serum (II)c 102% - 107% 88% - 96% 
Total assay imprecision (II)d   
 Lower pool 7.2% 9.7% 
 Higher pool 6.0% 6.7% 
Within-run imprecision (II)d   
 Lower pool 5.4% 6.9%  
 Higher pool 3.6% 4.1 % 
Mean relative difference (95% CI)   
 
Between serum and                                                                                   
heparin plasma (II) 
4.4%                                                    
(-19.8% to 28.6%) 
5.7%                                                             
(-20.8% to 32.3%) 
  
Between heparin plasma and heparinized 
whole blood with hematocrit correction (III) 
15.7%                                                       
(-10% to 42.3%) 
12.5%                                                             
(-9.2% to 34.3%) 
a Mean of zero standard + 3SD 
b Lowest sample concentration with coefficient of variation (CV) <20% 
c ACS serum (total PAPP-A assay) or pregnancy serum (complexed PAPP-A assay ) added to three serum 
samples of other ACS patients 
d Determined according to GLSI guideline EP5-A (Total PAPP-A assay: ACS serum lower pool 4.9 
mIU/L, higher pool 15.9 mIU/L; Complexed PAPP-A assay: pregnancy serum lower pool 3.1 mIU/L, 
higher pool 10.0 mIU/L) 
 
5.2.2 Evaluation of clinical performance (IV) 
For the clinical evaluation of the developed method for free PAPP-A detection we analysed 
serum samples from 267 NSTE-ACS patients. Median free PAPP-A in the admission sam-
ples of these patients was 1.43 [25th,75th percentiles; 1.13,1.95] mIU/L and 65.9% of the 
patients exceeded the 97.5th percentile of the apparently healthy individuals (II). Free 
PAPP-A in the admission sample correlated only weakly with admission cTnI (r=0.15, 
p=0.012), 24 h maximal cTnI (r=0.12, p=0.043) and CRP (r=0.17, p=0.005). 
Within the follow-up period of 12 months, 21.3% of the patients experienced an adverse 
event, i.e. had a new nonfatal MI, died or had an MI and died. When the patients were 
grouped according to PAPP-A tertiles (<1.27, 1.27-1.74, >1.74 mIU/L) there was a signifi-
cant difference between the tertiles in the number of patients who had an adverse event and 
the frequency of events increased with admission free PAPP-A (13.5%, 20.2%, 30.3% 
accordingly; p=0.02). In multivariate analysis with adjustment for age and ischemic ECG 
findings free PAPP-A was found to be an independent predictor of adverse events (free 
PAPP-A >1.74 mIU/L, risk ratio 2.0 [95% CI 1.0-3.9, p=0.05]) as were also positive 
maximal cTnI and CRP above 2.0 mg/L.The combination of free PAPP-A <1.27 mIU/L 
and negative maximal cTnI identified a low-risk patient group while the highest risk was 
seen in patients with free PAPP-A >1.74 mIU/L and positive maximal cTnI. 
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Total PAPP-A had an inferior performance when compared to free PAPP-A in predicting 
adverse cardiac events. The total PAPP-A concentration in the admission sample exceeded 
the total PAPP-A 97.5th percentile of healthy individuals only in 6.4% of the patients. The 
frequency of adverse events did not differ significantly between total PAPP-A tertile 
groups (<1.98, 1.98-2.99, >2.99 mIU/L; 19.1%, 19.1%, 23%; p=0.54). Moreover, total 
PAPP-A was not found to be an independent predictor of adverse events in multivariate 
analysis.  
5.3 Effects of heparin products on PAPP-A 
5.3.1 In vivo effects (V) 
When PAPP-A levels were studied in haemodialysis patients, it was noticed that the circu-
lating levels of free PAPP-A increased significantly and very rapidly after the start of the 
dialysis procedure (Fig.12A). This release was found to be caused by the intravenous bolus 
of LMWH as the increase was not seen at the beginning of the dialysis session in patients 
with heparin-free procedure. Moreover, in those patients who received delayed LMWH 
bolus the free PAPP-A increase coincided with LMWH delayed administration. After the 
peak value the concentration of free PAPP-A decreased rapidly. There was high variation 
between patients in the magnitude of the heparin product induced free PAPP-A release. 
The circulating concentrations of free PAPP-A were also followed in stable CAD patients 
during elective angiography. The patients received UFH intravenously at the beginning of 
the procedure and similar rapid elevations in free PAPP-A were seen as in the dialysis pa-
tients, although the response did not seem to be equally high (Fig.12B). Interestingly, with 
one patient who was treated with PCI and who received additional boluses of UFH, re-
peated free PAPP-A increases were seen coinciding with the UFH boluses. Complexed 
PAPP-A did not increase significantly in any of the dialysis or angiography patients. 
Figure 12. Free PAPP-A concentrations in serum samples of A) haemodialysis patients and B) patients 
undergoing elective angiography. 
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5.3.2 In vitro effects (V, unpublished) 
The effect of heparin products on PAPP-A concentrations was also studied in vitro. With 
whole blood samples from haemodialysis patients anticoagulated by EDTA, citrate or hi-
rudin it was revealed that LMWH or UFH in treatment concentrations did not cause an 
increase in free PAPP-A concentration in plasma. Moreover, no difference was seen in free 
PAPP-A levels of samples collected in heparin anticoagulated tubes when they were com-
pared to samples collected in tubes with other anticoagulants or serum tubes. Thus, it is 
unlikely that the blood cells are the origin of free PAPP-A that becomes released into the 
circulation due to heparin injection. Furthermore, the results confirm that the PAPP-A in-
crease detected is not a result of an artefact caused by the effect of heparin on the detection 
method. 
In gel filtration studies recombinant PAPP-A in buffer or serum eluted from the column 
significantly later than recombinant PAPP-A in heparin plasma or recombinant PAPP-A in 
serum with LMWH (Fig. 13A). A similar effect was seen when the PAPP-A elution profile 
of an ACS patient serum sample was compared to that of an ACS patient heparin plasma 
sample (Fig. 13B). Thus, the apparent molecular weight of recombinant/free PAPP-A put 
in heparin product containing solution appears to be larger than that of recombinant/free 
PAPP-A without a contact with a heparin product. Moreover, the molecular weight of re-
combinant PAPP-A in contact with UFH (the form of heparin in heparin plasma) seemed to 
be larger than the molecular weight of recombinant PAPP-A in contact with LMWH (Fig. 
13A). 
 
Figure 13. Total PAPP-A assay relative signals (% of maximum) of the gel filtration fractions of A) 
recombinant human PAPP-A (rPAPP-A) containing samples and B) samples from a pregnant woman and 
an ACS patient. (25 µL fractions collected between elution volumes 0.9 mL and 1.9 mL) 
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6.1 PAPP-A forms 
Our results implied that the form of PAPP-A which becomes released into the circulation in 
ACS is not complexed with proMBP as PAPP-A in ACS serum was not detected with 
proMBP reactive antibodies. The difference in the molecular size between PAPP-A in 
pregnancy serum and PAPP-A in ACS serum suggested that the PAPP-A form in ACS 
circulation could represent the free noncomplexed dimeric form of PAPP-A rather than 
PAPP-A complexed with other molecules. Complexation with smaller molecules possibly 
involving only one PAPP-A subunit cannot be excluded. However, to date, such complexes 
have not been reported. 
As PAPP-A has been found in ruptured and eroded coronary plaques but not in stable 
plaques (Bayes-Genis et al., 2001a) and as PAPP-A concentration in blood is associated 
with the risk for adverse cardiac events (see section 2.4.2), it seems possible that PAPP-A 
has an active role in the progression of atherosclerotic plaques to vulnerable state. The role 
of PAPP-A in various systems appears to be linked to its enzyme activity (see section 2.3) 
and hence to the release of IGFs from the binding proteins. It is noteworthy that only the 
free form of PAPP-A seems to be active (Overgaard et al., 2000; Chen et al., 2002). Thus, 
it would be rational that PAPP-A exists in and is released from the plaque in the free form. 
However, the form of PAPP-A in atherosclerotic plaque has not been yet confirmed by 
immunohistochemical staining because free PAPP-A specific antibodies have been lacking. 
The mechanism of ACS associated free PAPP-A release to circulation (in the absence of 
heparin products) is still unknown. 
We analysed the different forms of PAPP-A in a reference population. The results showed 
that in apparently healthy individuals free PAPP-A levels are close to zero and that the 
baseline total PAPP-A concentration detectable in the samples is almost exclusively com-
prised of the complexed form of PAPP-A. These results imply that possibly, especially at 
low total PAPP-A levels, free PAPP-A could better distinguish between ACS patients with 
an ACS-associated elevation of free PAPP-A form from those non-ACS individuals with 
naturally occurring higher total PAPP-A baseline caused by complexed PAPP-A (Fig. 14). 
Importantly, supporting evidence of this was obtained in this thesis when the point-of-care 
method developed for free PAPP-A detection was clinically evaluated with ACS patient 
samples. Free PAPP-A was shown to be superior to total PAPP-A as a prognostic marker. 
Thus, free PAPP-A seems to be more specific marker than total PAPP-A in reflecting the 
adverse processes associated with worse outcome in ACS patients. 
The characteristics of the PAPP-A assays that have been used in other studies related to 
ACS are shown in Table 6. The assays are expected to detect total PAPP-A as specific 
binders for free PAPP-A have not been available, although specifications on PAPP-A 
forms detected are not available for all assays. It is noteworthy that for one of the assays 
(Kryptor BRAHMS) it has confusingly been stated that the assay detects PAPP-A/proMBP 
complex (Beaudeux et al., 2003). However, assays initially designed for PAPP-A meas-
urement in pregnancy, which is the case with this assay, would be of little use when study-
ing samples from ACS patients, if they detect only the complexed form of PAPP-A. With 
such assays the ACS-related free PAPP-A elevations would be missed (Qin et al., 2006a). 
In contrast, elevated levels have been reported in ACS by Hájek and colleagues (2008) 
using this assay.  
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Figure 14. The hypothetical distributions of total PAPP-A and free PAPP-A in ACS patients and healthy 
individuals. Because complexed PAPP-A baseline levels vary between healthy individuals, it is suggested 
that, especially at low free PAPP-A elevations, total PAPP-A is not as good in discriminating between 
ACS patients and healthy individuals as free PAPP-A, which is not affected by complexed PAPP-A. 
 
Table 6. Characteristics of the assays that have been used for PAPP-A detection in studies related to ACS. 
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aAll assays with sufficient details reported are two-site immunoassays using polyclonal antibodies (pab) or mono-
clonal antibodies (mab) at each site 
bAbbreviations: ELISA, enzyme-linked immunosorbent assay; HRP, horseradish peroxidase 
c Specificity for PAPP-A/proMBP complex has been reported which is in contradiction with the elevations detected by 
this assay in ACS patients (Hajek et al. 2008) 
d http://www.demeditec.com/en/products/product_details/backPID/23/proview/papp_a_ultra_sensitive_elisa/beginat/ 
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The reported (total) PAPP-A baseline levels in healthy individuals have varied remarkably 
(Fig. 11). Our results of total PAPP-A concentration in an apparently healthy reference 
population lie near the lower end of results of the previous studies (Fig. 15). The differ-
ences between studies may be due to the use of different assays involving different anti-
body combinations. However, calibration related problems may also exist, as reported 
mean or median levels of healthy individuals have varied significantly even between stud-
ies using the same assay (Fig. 15). For some assays, the detection limit does not seem low 
enough to reliably detect the PAPP-A concentrations in healthy individuals (detection lim-
its >3 mIU/L) (Table 6).  
Figure 15. PAPP-A concentrations measured in apparently healthy control cohorts in different studies by 
different assays. (Closed circles indicate the mean concentration ±SD; open squares represent the 25th, 50th 
and 75th percentiles.) 
6.2 Point-of-care assays for free PAPP-A measurement 
In this thesis study a point-of-care method was developed for the detection of free PAPP-A. 
The performance characteristics were shown to be good for the purpose of ACS sample 
analysis. The method enables rapid and sensitive detection of free PAPP-A in serum, hepa-
rin plasma and heparinized whole blood samples. The possibility to use whole blood as the 
sample matrix is especially important for point-of-care assays as it removes the need of 
centrifugation and plasma extraction as sample preparation steps and thus enables faster 
sample analysis. 
The method developed for free PAPP-A measurement involves the use of two assays. 
However, the ideal approach would be a single direct assay that specifically detects only 
the free form of PAPP-A. The use of two assays results in larger reagent costs, more time 
spent per analysis of a sample and also in a higher limit of detection due to the imprecision 
of the two assays accumulating in the final result. The reason for the use of the two assay 
approach is that free PAPP-A specific antibodies were not available at the time of the de-
velopment of these assays and have only very recently started to emerge. In future studies, 
direct assays for free PAPP-A should be developed to avoid the limitations of the two assay 
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approach. Especially in the case of sensitivity it would be very interesting to see how low 
the circulating levels of free PAPP-A are in healthy individuals. This would presumably 
better reveal the power of free PAPP-A to discriminate between normal population and 
ACS patients at risk.  
Assays for the enzyme activity of PAPP-A could also serve as an option for free PAPP-A 
measurement as complexation with proMBP inactivates PAPP-A. However, some PAPP-A 
may be ineffectively inactivated by proMBP as low residual activity has been detected with 
PAPP-A/proMBP complex purified from pregnancy serum (Overgaard et al., 2000). This 
may negatively affect free PAPP-A measurement with the activity approach.  
The clinical evaluation of the free PAPP-A detection method developed revealed that free 
PAPP-A is an independent prognostic marker in ACS patients when measured in the ad-
mission sample. The prognostic information of free PAPP-A was additive to that of cTnI 
and CRP implying that free PAPP-A may reflect other processes than these markers and 
could offer benefit when used together with these markers. However, as a new ACS related 
marker, free PAPP-A competes with the other emerging markers and therefore should also 
provide additional or superior prognostic information when compared with them. Espe-
cially, brain-type natriuretic peptide (BNP) and N-terminal proBNP, markers associated 
with heart failure, have also shown significant promise in improving risk prediction of ACS 
patients (Morrow et al., 2007; Bonaca and Morrow, 2008) and thus it would be important 
to compare free PAPP-A with these markers. Finally, to become accepted in use, a new 
ACS related marker should be able to guide the treatment of patients. However, for this 
aim large further studies are required. As knowledge on the pathological processes leading 
to certain biomarker elevation in the circulation increases, new treatment methods may be 
discovered that specifically lower the biomarker related risk. 
6.3 Effects of heparin products on PAPP-A 
By analyzing samples from haemodialysis patients and patients undergoing elective an-
giography, it was shown that intravenously administered heparin products (LMWH and 
UFH) induce a rapid increase in circulating free PAPP-A. The mechanism of PAPP-A 
release into the circulation by heparin products is unknown. However, release from the 
endothelium of the vasculature has been suggested (Terkelsen et al., 2009). As previously 
mentioned, the dimeric recombinant PAPP-A has been shown to bind to cell surfaces by 
the GAG binding site and heparin has been shown to release recombinant PAPP-A from 
the cell surface (Laursen et al., 2002b). The rapid appearance of free PAPP-A in blood as a 
response to heparin products supports the idea of endothelium being the site of release as it 
is readily accessible for the intravenously administered heparin and optimal for the direct 
rapid release of PAPP-A into the circulation.  
The magnitude of the heparin product induced free PAPP-A release seemed to differ sig-
nificantly between patients in our study. The reason for this is unknown. The small number 
of patients included in the study does not allow reliable analysis of associations between 
free PAPP-A release and interesting variables such as the presence or extent of CAD or the 
future risk of death or cardiac events. Thus, studies with a larger number of patients would 
be interesting in this respect. 
The reason for lower free PAPP-A responses in angiography patients than in dialysis pa-
tients is unclear. The possible explanations include lower ability of UFH than LMWH to 
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release free PAPP-A or lower reserves of free PAPP-A to be released by heparin in CAD 
patients than in dialysis patients. Studies that would involve dialysis patients receiving 
UFH instead of LMWH as well as angiography patients receiving LMWH instead of UFH 
could shed more light on this matter. 
We also studied the effect of heparin products on PAPP-A in vitro with gel filtration and 
confirmed the previous findings of others obtained with other techniques that PAPP-A 
interacts with heparin (Laursen et al., 2002b; Weyer et al., 2004; Conover et al., 2007). In 
our studies heparin products increased the apparent molecular weight of endogenous free 
PAPP-A and recombinant PAPP-A. A rational explanation for this phenomenon would be 
the binding of free PAPP-A molecules with heparin molecules. The size of UFH commonly 
varies between 3 and 30 kDa. Binding of two 30 kDa UFH molecules to PAPP-A dimer 
would increase the mass similar extent as the binding of two proMBP subunits. Accord-
ingly, in the gel filtration studies the apparent size of PAPP-A in ACS heparin plasma was 
the same as that of complexed PAPP-A in pregnancy serum (Fig. 13B). However, in addi-
tion to changing the mass, heparin products may also alter the elution of PAPP-A from the 
gel filtration column in other ways. Being highly negatively charged, heparin changes the 
electric charge of the molecule it binds to. However, there was a relatively high salt con-
centration in the elution buffer intended to prevent the effect of electrochemical forces on 
the elution. The heparin binding of PAPP-A may also have some conformation altering 
effects on the very large PAPP-A molecule. As only the elution of globular molecules is 
linearly dependent on the molecular weight, a significant conformation change may have a 
larger effect on the elution than expected by the actual change in molecular weight.  
It has been shown in the studies summarized here that LMWH or UFH increase free PAPP-
A in the blood of haemodialysis and angiography patients and others have reported results 
implying that UFH may do so in STEMI patients (Terkelsen et al., 2009). As was discussed 
in section 2.4.6, the effect of heparin products on circulating PAPP-A levels may have 
significantly influenced at least some of the previous studies related to PAPP-A in ACS 
and other conditions. It is very important that in the future this phenomenon is acknowl-
edged when designing new studies. However, it should be noted that no patients who had 
received heparin product treatment before admission sample were included in our study 
described in section 5.2.2 (IV) and thus these results were not biased by the heparin effect. 
Importantly, although ACS patients are often medicated with heparin products, this effect 
does not render PAPP-A ineffective as a marker in this condition because the clinical rele-
vance of PAPP-A as a biomarker would be as a very early diagnostic or prognostic marker 
in the situation when the diagnosis is still unknown and hence no medication has yet been 
administered. 
The assays used for the analysis of PAPP-A may also be affected by the LMWH or UFH 
medication of the patients. It has been noticed that some assays are significantly negatively 
affected by heparin probably due to masking of the antibody epitopes on PAPP-A and 
therefore heparin plasma is not recommended as the sample material for such assays (Qin 
et al., 2002a; Spencer, 2003). Thus, serum is generally the preferred sample material for 
the PAPP-A assays that have been used in the ACS related studies (Table 4). However, it is 
imperative to confirm that the PAPP-A assays used are not affected by heparin-PAPP-A 
interaction also when serum samples from patients medicated with heparin products are 




Although cardiac troponins as markers of myocardial necrosis have become a widely used, 
important diagnostic tool in ACS, in recent years there has been a quest to find new mark-
ers that would improve the management of patients with ACS symptoms. A new marker 
should fulfil certain criteria to become useful in ACS patient care: 1) It should discriminate 
between healthy individuals and patients at cardiac risk with high sensitivity early in the 
course of ACS. 2) It should be detectable by an analysis method that enables a rapid reli-
able measurement preferably in a point-of-care setting. 3) It should give additional infor-
mation when used in a multimarker approach combining biomarkers reflecting the com-
plementary pathological pathways associated with ACS. 4) It should be able to guide the 
treatment by helping to determine the aggressiveness of care (Maisel et al., 2006; Bonaca 
and Morrow, 2008; O'Donoghue and Morrow, 2008). PAPP-A is one of the new candidate 
markers under investigation. 
In this study it was revealed that PAPP-A is released into the circulation of ACS patients in 
a form that differs from the form of PAPP-A in pregnancy serum. A point-of-care detection 
method was developed for this ACS-related PAPP-A form and the performance of the 
method was evaluated with different sample materials and clinical samples from ACS pa-
tients. In addition, we also studied the effect of heparin products, which are widely used as 
medication in ACS patients, on the PAPP-A molecule and on the concentrations of PAPP-
A forms in the circulation. 
The main conclusions based on the original publications are: 
I PAPP-A is released into the circulation of ACS patients in a noncomplexed free 
form as this form is not detected by antibodies reactive against proMBP. Further, the 
molecular weight of this form is significantly smaller than that of the PAPP-
A/proMBP complex found in pregnancy serum.  
II Free PAPP-A can be analysed rapidly and efficiently with the two-assay point-of-
care approach developed based on time-resolved immunofluorometric assays. Non-
pregnant individuals seem to generally have a low basal level of complexed PAPP-A 
in the circulation that is responsible for detectable total PAPP-A concentrations, 
while the concentration of free PAPP-A in non-pregnant non-ACS individuals ap-
pears to be close to zero. Therefore, free PAPP-A may better discriminate between 
patients with pathological elevations and healthy individuals than total PAPP-A 
which is also affected by the fluctuating baseline levels of complexed PAPP-A. 
III In addition to serum and heparin plasma, heparinized whole blood is eligible as a 
sample matrix for the point-of-care method developed for free PAPP-A detection. 
The ability to use whole blood as the sample material obviates the need for plasma 
separation prior to analysis and thus saves time. 
IV Free PAPP-A analysed in the admission sample (before medication with heparin 
products) with the method developed is an independent predictor of MI and death in 
NSTE-ACS patients. Furthermore, as a prognostic marker free PAPP-A seems to be 
superior to total PAPP-A and also gives additional prognostic information when 
combined with cTnI. 
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V Intravenous administration of LMWH or UFH induces a rapid release of free PAPP-
A to the circulation in haemodialysis patients and in patients undergoing elective 
angiography. To avoid bias in studies due to this effect, PAPP-A levels should only 
be measured in patients without or before the initiation of heparin product treatment. 
Additionally, with gel filtration studies with free PAPP-A containing ACS blood and with 
recombinant PAPP-A we confirmed that heparin interacts with PAPP-A, which leads to an 
increase in the apparent molecular weight of PAPP-A. This is important to be kept in mind 
when using PAPP-A assays with samples from patients treated with heparin products as the 
assays may be affected by the interaction. 
As the prognostic power of free PAPP-A in ACS patients was confirmed, one objective for 
future studies is to investigate whether elevated free PAPP-A in the admission sample, 
possibly along with other new markers or troponins preferably measured with highly sensi-
tive assays, could help in guiding the treatment of patients with ACS symptoms. Another 
intriguing subject for further studies that arose from the results of this thesis relates to the 
possible information linked to the extent of free PAPP-A release induced by heparin prod-
ucts. It would be interesting to investigate whether the amount of released free PAPP-A, 
which was shown to vary significantly between the study subjects in this thesis, reflects the 
burden of atherosclerotic plaques or, more specifically, the prevalence of vulnerable 
atherosclerotic plaques in the patients, or is associated with the risk for adverse cardiac 
events. 
In conclusion, free PAPP-A is an interesting novel circulating biomarker that seems to 
perform better than total PAPP-A in predicting the risk for adverse events in ACS patients 
when measured at the time of admission. The developed point-of-care assays represent a 
rapid and easy method for the measurement of this PAPP-A form in serum, heparin plasma 
or heparinized whole blood. However, the interaction of heparin products with PAPP-A 
and the release of PAPP-A into the circulation by treatment with heparin products may 
have influenced the previous studies on PAPP-A in ACS and should be considered when 
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